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Abstract: 
 
Approximately 42 new arene-perfluoroarene compounds were synthesised by the 
reaction of pentafluorophenyl derivatives (C6F5R; R= CN, Br, Cl, I, CHO, CF3, H) 
with imidazole, benzimidazole, parazole, indazole and their derivatives such as 2-
methylimidazole, 4-methylimidazole, 2-phenylimidazole and 2-methylbenz-
imidazole. Attempts to synthesize 1-(2,3,5,6-tetrafluoropyridyl)pyrazole and 1-
(2,3,5,6-tetrafluoropyridyl)indazole were unsuccessful. However, these reactions 
were achieved using different solvents, varying amounts of solvents and varying 
temperatures. Various chemical analytical techniques, such as NMR spectroscopy, 
mass spectrometry, infrared spectroscopy, single-crystal X-diffraction and micro-
elemental analysis, were used to characterise the compounds. The crystallization 
of these compounds was performed by the slow evaporation of their solutions in 
different solvents at ambient temperature. Single crystal structures were obtained 
for  1-(2,3,5,6- tetrafluoropyridyl)-2-methylbenzimidazole, 1-(4-bromo-2,3,5,6-
tetrafluorobenzyl)-3-benzyl-4-methylimidazolium bromide and 1-(2,3,5,6-
tetrafluoropyridyl)-3-benzyl-4-methylimidazolium bromide and this result has 
shown that π-π stacking interactions have an essential role in the packing of these 
compounds. 
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1.Chapter One: 
 
 
1.1. Introduction: 
  
    stacking interactions between arenes and perfluoroarenes has potential in 
crystal engineering 
[1]
, and has received attention as a result of this. The 
interactions are a mixture  of electrostatic interactions and Van der Waals [2], 
between slipped parallel stacks of Ar
H
-Ar
F [3]
. These interactions have been known 
over four decades 
[4]
, but only in the past few years, they have been used as a main 
tool of crystal engineering 
[5]
, synthesis and control of molecular structure to 
achieve functional properties. Due to their ability of arene-perfluoroarene 
synthons to incorporate easily into molecules 
[6]
, this lead to enhance their crucial 
role in various fields such as biology 
[3]
, pharmaceutical industry, supra-molecular 
chemistry 
[7]
 and crystal engineering 
[7]
. This thesis will investigate molecules that 
contain both polyfluoroaryl and aryl groups. These are based on nitrogen 
containing heterocycles, in particular imidazole and benzimidazole compounds.     
 
 
 
 
 
 
2 
 
1.2. Arene-Perfluoroarene Interactions: 
 
 
Figure 1: The different geometries of polyfluoroaryl-aryl group interactions 
[8]
. 
 
It has been found that for the perfluoroarene–arene synthons the contact 
C−H…F−C is the factor that dominates the stability of these synthons. 
Hexafluorobenzene (mp 5.0˚ C) and benzene (mp 5.4˚ C) have been used by 
Patrick and Prosser to form the first complex (mp 23.7˚ C) using this type of 
interaction. As a model of  perfluoroarene–arene synthons [9], C6H5–C6F5 synthon 
has been studied using CCSD(T) ("coupled cluster single and doubles with 
perturbative triples") method, and it has been found that The T-shaped geometries 
have the lowest stability (ΔE = −1.74 and −0.88 kcalmol-1), whereas, the parallel 
displaced geometry has the highest stability (ΔE = −5.38 kcalmol-1), followed by 
the face-to-face geometry (ΔE = −5.07 kcalmol-1) (Fig. 1), and the drop of the 
stability is because of the reduction of dispersion forces and undesired type of 
electrostatic interactions.  To study the effect of substituent on this synthon 
(C6H5X–C6F6), it has found also that the face-to-face motif is less favorable than 
the parallel displaced motifs. Other complexes have been synthesized, such as 
methyl-substituted arene (p-xylene, mesitylene, durene and hexamethylbenzene) 
with hexafluorobenzene, and the crystallographic data of these compounds has 
shown a combination of stacking with edge to face     stacking interactions. 
3 
 
Studies of hexafluorobenzene-arene complexes by using spectroscopy and 
refractometry have been shown that there are VdW and electrostatic interactions 
and other charge transfer interactions, consider     stacking interactions. It has 
also been shown that the face to face geometry of these interactions between the 
compounds that pack on the top of each other can have variable orientations 
[8]
, in 
which, it can be columnar geometry with angle of 90˚ θ or slipped geometry with 
angle of 45˚ θ, with longer distance in the first geometry than the second (Fig. 2) 
[6]
. 
 
This project will aim to synthesis new arene-perfluoroarene compounds. 
Imidazole, benzimidazole, pyrazole, indazole and their derivatives are the starting 
materials in this project, and these will be introduced individually in each chapter. 
The other starting material is a derivative or analogue of  hexafluorobenzene 
(HFB). HFB has a planar aromatic ring, like benzene, with a symmetry of D6h, a 
dissociation energy of  ≥ 0.5 eV, an electron affinity of ≥ 1.8 + 0.3 eV of the front 
endothermic negative ion charge transfer reaction and 3.45 eV of E. A. 
[10]
. It was 
first prepared as a molecular complex with benzene in 1960 
[9]
. This was followed 
by similar complexes of its derivatives such as  octafluoronaphthalene (OFN) with 
trans-stilbene or trans-azobenzene, pentafluorophenyl group with chiral amino 
alcohol 
[11]
, phenyl-perfluorophenyl complex 
[12]
, pentafluorobenzoate in 
Cu(py)2(pfb)2 and Cu(py)2(pfb)2(H2O) 
[13]
, and it has been found that all these 
complexes are sharing common properties. First of all the arene and 
perfluoroarene aromatic rings are perseverant in the 1:1 complex. Secondly, the 
complexs have higher melting points than the starting materials. Thirdly, the 
infinite stacking of their components leads to crystal structures with different 
geometries 
[14]
. In this project, the derivatives of HFB that have been used as a 
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starting materials to form arene-pentafluoroarene complexes are 
tetrafluorophthalonitrile, pentafluorobenzaldehyde, 3-chloro-2,4,5,6-
tetrafluoropyridine, 2-pentafluorobenzonitrile, Pentafluorobenzaldehyde, 
tetrafluoropyridine, 2,3,4,5,6-pentafluorobenzonitrile, penatfluoropyridine, 
bromopentafluorobenzene, 4-bromo-2,3,5,6-tetrafluorobenzotrifluoride, 
pentafluorobenzene , Iodo-pentafluorobenzene , 2,3,4,5- tetrafluorobenzonitrile, 
2,3,5,6-tetrafluoropyridine, 2,3,5,6-tetrafluorobenzonitrile, 2,4,5-
trifluorobenzonitrile, 2,3,4-trifluorobenzonitrile, 2,3,5- trifluoropyridine and 
octafluorotoluene. HFB and its derivatives are biologically active, 
hexafluorobenzene solvate of hexamelamine shows anticancer activity 
[15]
, and 
different instruments have been used to study these compounds. For example, in 
CH3CN, NMR and CD spectroscopy have been used to study the effect of 
pentafluorobenzene on the secondary structure of peptoids, oligomers of N-
substitued glycines 
[8]
. 
 
Figure 2: The different orientations of face to face geometry 
[6]
. 
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To study these interactions, the octafluoronaphthalene−acenaphthene complex has 
been prepared and crystalized by Collings. The crystal structure of this complex, 
has an infinite column of alternating OFN and acenaphthene with a small distance 
(d) between the aryl and perfluoroaryl rings and slip angles (θ), angles (ϕ) and 
stack shifts (s) as shown below (Fig. 3) 
[16]
. 
 
Figure 3: Alternating stacking of octafluoronaphthalene and acenaphthene 
[16]
. 
 
And it has been shown that favorable interaction is possible with inter-planar 
separation over than 4 Å, and this has been confirmed during studying 1-
(2,3,4,5,6-pentafluorobenzyl)-3-benzylimidazolium bromide, which has an inter-
planar separation of 4.3 Å 
[17]
 (Fig. 4, 5, & 6). 
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Figure 4: Inter-planar separation in the packing of arene-perfluoroarene synthons 
[17]
. 
 
 
 
Figure 5: 1-(2,3,4,5,6-pentafluorobenzyl)-3-benzylimidazolium bromide 
[17]
. 
 
 
 
Figure 6: Face to face packing of 1-(2,3,4,5,6-pentafluorobenzyl)-3-
benzylimidazolium bromide 
[17]
. 
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However, there are similar complexes and salts to arene-perfluoroarene 
complexes and imidazolium salts in this project have been synthesized by an easy 
route and good yields such as the complexes that have been reported by Fujii et al, 
which are (4'-nitrotetrafluorophenyl) imidazole, I-(2'-nitrotetrafluorophenyl) 
imidazole, l-(4'-formyltetrafluorophenyl) imidazole, 1-(4'-
formyltetrafluorophenyl) imidazole ethyl hemiacetal, 4'-
ethoxycarbonyltetrafluorophenyl) imidazole, 1-(4'-bromotetrafluorophenyl) 
imidazole, 1-(4'-chlorotetrafluorophenyl) imidazole, l-(2'-chlorotetrafluorophenyl) 
imidazole, (2',4'-dibromotrifluorophenyl)imidazole, (2'-bromo-3',5',6'-
trifluorophenyl)imidazole, and it has shown that the reactivity of PFB has been 
achieved at room temperature with NO2 and CN as substituent groups, whereas , it 
has not been achieved with Me or MeO groups even with strong base at high 
temperature (over 99 C°) 
[18]
 as shown below in (Fig. 7) and (Table. 1). 
NH N
R
F
F
F
F
F
N
N
R
F
FF
F
N
N
F R
F
F
F
+ +
                                              (I)                                                    para(p)                          ortho(o) 
 
a) R = CN b) R = NO2 c) R = CHO 
d) R = CO2C2H5 
e) R =CO2H f) R = I g) R = Br 
h) R = Cl 
i) R = F j) R=H k) R = CH3 
l) R = OCH3 
 
Figure 7: The general synthesis reaction of polyfluoroaryl and imidazole 
compounds with their derivatives 
[18]
. 
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I solvent 
Reaction conditions1 Product yields (%) 
Base         
Time. 
hrs 
p o 
Ia C6H5CN THF  r. t.
2
 3 83.8  
Ib C6H5NO2 THF  r. t. 4 51.8 13.9 
Ic C6H5CHO THF  r. t. 20 83.5  
Id C6H5CO2C2H5 THF  65 10 81.5  
Ie C6H5 CO2H THF  65 10   
If C6H5I DMSO  80 43 70.4  
Ig C6H5Br DMSO  80 96 40.3  
Ih C6H5Cl DMSO  100 40 65.9 2.8 
Ih C6H5Cl DMSO KOH
3
 80 4 38.4 4.1 
Ih C6H5Cl THF KOH
3
 60 66 26.8 2.4 
Ih C6H5Cl tBuOH KOH
3
 80 20 54.4 4.3 
Ii C6H5 DMSO KOH
3
 80 24   
Ij C6H5H DMSO KOH
3
 55 3 73.6  
Ik C6H5CH3 DMSO  100 24   
Il C6H5OCH3 DMSO  100 24   
 
1
 Imidazole 10 mol; Pentafluorobenzene  (I) 20 mol; solvent 30 ml. 
2  mbient temperature (13  16  C).  
Table 1: Nucleophilic substitution of pentafluorobenzene (I) with imidazole 
[18]
. 
 
The similar salts to this project, that have been prepared are 1-(2,3,5,6-
tetrafluoropyridyl)-3-benzylimidazolium bromide (Fig. 9), which has been done 
by Saunders. G; with     stacking interactions to control the structure, which 
provided an infinite two directional face-to-face packing geometry as in this 
project (Fig. 8) 
[5]
.   
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Figure 8: 1-(2,3,5,6-tetrafluoropyridyl)-3-benzylimidazolium bromide 
[5]
. 
 
Figure 9: Two directional face-to-face packing geometry 
[5]
. 
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1.3. Crystal Engineering: 
Crystal engineering is the study of structures and the control of packing of 
molecules or ions (synthons) to enhance the materials’ structures and achieve 
functional properties 
[19]
. 
In     stacking interactions the nuclei of carbon atoms each have a positive 
charge (+1) surrounded by two negative charges (-1/2) with δ distance between 
these opposite charges (Fig. 10). The possible motifs that can be formed in this 
system have been explained by Hunter and Sanders, and they are the repulsion 
face-to-face geometry, attractive offset face-to-face geometry and attractive edge-
to-face geometry 
[20]
. The face to face geometry can be attractive if the 
polarization of the two aromatic rings is different. This can be achieved by using 
atoms with electronegativities different to carbon and hydrogen (Fig. 11) 
[21]
. 
 
 
Figure 10: The various geometries of a π system, a) edge to face geometry, b) 
offset face to face geometry, c) face to face geometry 
[22]
.  
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Figure 11: The effect of the polarized substituents on the attraction force of the 
face to face geometry 
[23]
. 
 
By modifying the polarization favorable     stacking interactions can be 
achieved. This can be done based on the position and number of the polar 
substituents, and this has been investigated through studying the packing of 
different aromatic rings that have variable numbers and positions of nitrogen 
atoms in aryl groups, such as pyridine, pyridazine, pyrimidine, pyrazine, 
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quinolone, phthalazine, quinazoline, quinoxaline and phenazine (Fig. 12). Studies 
have confirmed that adjusting the polarization affects the packing and allows for 
the best orientation to have the desired face to face     stacking interactions 
[21]
. This type of interactions can be interpreted using an electron donor-acceptor 
model, which has been confirmed by Chang et al reference, who synthesized new 
compounds and found crystal packing with favourable offset face to face 
geometry as a result of the different polarization between aromatic rings. These 
compounds are 2,5-di(pyrimidin-2-yl)thieno[3,2-b]thiophene, 2,5-di(pyrimidine-
5-yl)thieno[3,2-b]thiophene, 2,5-di(pyridine-5-yl)thieno[3,2-b]thiophene, 2,5-
bis(4-(trifluoromethyl)phenyl)thieno[3,2-b]thiophene and 2-thieno[3,2-
b]thiophene-2-yl-benzothiazole 
[24]
. So      stacking interactions can be 
attractive or repulsive. The inorporation of heteroatoms can overcome the 
repulsion in this type of interaction, and the orientation also is able to provide 
attraction forces 
[20]
 (Fig. 13). 
N  
pyridine 
N
N  
pyridazine 
 
N
N  
pyrimidine 
N
N  
pyrazine 
N  
quinolone 
N
N
 
phthalazine 
N
N
 
quinazoline 
N
N  
quinoxaline 
 
 
 
3 
 
N
N  
phenazine 
Figure12: Aryl groups containing different number and position of nitrogen 
atoms 
[21]
. 
 
 
Figure 13: Effect the orientation on the electrostatic interactions 
[25]
. 
 
 
There are other factors that can affect the geometry of these interactions. A study 
has been carried out by Zhang to investigate the effect of size and shape of face-
to-face dimers on the     stacking interactions, which consist of six condensed 
arenes of regular hexagonal (RH), eight ladder-shaped (LS) and eight wavy-linear 
all-trans conjugated alkene (Fig. 14) 
[26]
.  
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Figure 14: On the left side hand the different sizes of the different molecules have 
been represented by different colours such as a1 to a8, b1 to b8 and c1 to c5, 
whereas on the right hand side the delocalization of π-electrons has been shown 
by the electron density pictures of the largest molecules 
[26]
.   
 
He deduced that if the monomers have a decreased symmetry and an increase in 
their size, or vice versa, then the energy of these interactions will be affected by 
rotation. In the dimers with the same shape, only the shape of these monomers has 
the ability to control the distance of centroid-centroid      stacking interactions. 
He found there is a directly proportional relationship between the strength of 
    stacking interactions and the electron density, and reported that the face-to-
face geometry  [26].  
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In the 1980s, Ferguson and Diederich found that the main factor to control the 
stability of complexes is the electrostatic forces in the absence of charge transfer 
effect. They studied 2,6-disubstitued naphthalene derivatives interacting with 
cyclophenes in d4-methanol, using various substituents with low and high electron 
density, such as CH2OH, NH2, CH3, CO2H, NO2 and CN.  In 1987 edge to face 
geometry based on substituents that have different electron density was shown in 
the class of thymine receptors that had been synthesised by Hamilton and his 
colleaques 
[25]
. Partially extended helical theory has been used by Chesnut and 
Mosely to measure charge transfer complexes geometrically, which were similar 
to the crystal structures determined by XRD, and a slight increase in the stability 
can be achieved through the charge transfer bonds in these complexes 
[25]
.  
Another factor that has been investigated is the effect of substituents on the 
parallel-displaced geometry, which has been carried out by Arnstein and Sherrill. 
They found that the position of the (PES) potential energy surface could be 
positive or negative (Fig. 15). They also found that the horizontal fluorine 
substituent leads to decrease the energy of     stacking interactions, whereas, 
hydroxyl substituent leads to enhance the dispersion interactions 
[27]
.  
 
 
Figure 15: Substituted benzene–benzene complexes in (a) parallel-displaced over 
a vertex and (b) parallel-displaced edgewise orientations. X = H, F, CN, and OH 
[27]
.  
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In this project compounds containing both polyfluoroaryl and aryl groups and 
their potential for crystal engineering are investigated. Koizumi et al, have 
confirmed that the selectivity of inter-and intra-molecular A-D-A     stacking 
interactions between phenylene and two pyridinium rings can be affected by the 
type of substituents 
[28]
. In 2012 the effect of various substituents in different 
position was studied using the structure of racemic 2- and 4-substitued benzyl 
leucine diethyl amides. It has been found that, 4-NO2, 3-Me, 3-OMe, 3-NO2, 3F, 
3-Br and 3-Cl enhance the stability of     stacking interactions and lead to self-
assembly, whereas, 4-CN, 4-OMe, 4-Me, 4-Cl and 4-Br failed to self-assemble 
and enhance the stability of     stacking interactions. This difference arises 
because of some factors such as exchange repulsion, dispersion, induction and 
electrostatic forces, and two of them, which are electrostatic dispersion forces, 
have been reported to strongly affect the energy and direction of the interactions 
between the benzene dimers in T-shaped and slipped parallel geometries 
[29]
. 
Regarding the effect of anti-parallel and parallel mono-substituted benzene dimes 
on the energy of      stacking interactions, it has found that mono-substituted 
benzene dimers in parallel-displaced form leads to less stability than the 
antiparallel-displaced form of benzonitrile-phenyl, fluorobenzene-phenol and 
nitrobenzene-phenol 
[30]
.  
A study by Rashkin and Waters based on the Hunter and Sanders model has 
shown unusual substituents effect during their studying of meta and para-
substituted N-benzyl-2-(2-fluorophenyl)-pyridinium bromides. T-shaped 
geometry can be seen between the B and C aromatic rings through using the 
methylene group as a bridge. Water solubility can be provided through the 
pyridinium ring A, which led to the diastereomer of Ha and Hb. The energy using 
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different substituents (e.g. X=H, 4-CH3, 3-CH3, 3,5-(CH3)2,  4-CF3,  3-CF3, 3,5-
(CF3)2, 4-NO2,  3-NO2, 3,5-(NO2)2) has been measured (Fig. 16).  
 
  
Figure 16: Substituted meta and para-substituted N-benzyl-2-(2-fluorophenyl)-
pyridinium bromides 
[31]
. 
 
Based on the collected data they repoted that the magnitude of interaction can be 
affected by the orientation of two attached aromatic rings, which can be affected 
by the electron density in para-substituted N-benzyl-2-(2-fluorophenyl)-
pyridinium bromides using 4-NO3 as substituent, whereas using 3-NO3 substituent 
lead to higher rotation as a result of the attractive force between oxygen and 
hydrogen atoms, and this difference impact positively on other stacking 
interaction that involved DNA bases as substituted rings 
[32]
. Similar 
consequences have shown the importance of electrostatic and substituent effects 
on     stacking interactions, and this has been confirmed by Cockroft et al, 
through characterization of new synthetic supramolecular zipper complexes using 
NMR with chloroform as a solvent 
[33]
.  
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Cockroft et al, have confirmed the effect of electrostatic forces in controlling the 
non-covalent interactions between aromatic rings through supramolecular 
chemistry. They have measured this type of interaction using four complexes with 
double mutant cycles to quantify them. 
1
H NMR spectroscopy in CDCl3 was used 
for characterization. Various substituents have been used to show their different 
effects in the interactions of pentafluorophenyl and phenyl such as (NMe2, H, 
OMe, Cl, NO2), through comparison of their measured energies (Table. 2) with 
the Hammett constants (Fig. 17). They have found that substituents with low 
electron density lead to highly attractive forces in pentafluorophenyl. As a result 
these substituents lead to a positive surface, which makes it more attractive for 
substituents with high electron density. In contrast, the surface of aromatic phenyl 
ring has negative charge which makes it attractive for substituents with low 
electron density  
[34]
.  
  
Substituents X pentafluorophenyl phenyl 
NMe2 
H 
OMe 
Cl 
NO2 
-3.2 
-3.0 
-2.2 
-1.2 
-0.2 
+1.5 
+0.3 
+0.9 
 0.0 
-1.0 
 
Table 2: Values measured in CDCl3 at 293 K, and errors are 0.7-1.1 kJ mol
-1
 
[25]
. 
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Figure 17: Experimental aromatic stacking interaction energies (¢¢G) correlate 
with the Hammett substituent constant for X (óX). Interactions with phenyl (b) 
and pentafluorophenyl (O) are shown 
[34]
. 
 
Metal tris(bipyridine) complexes have been used to determine the effect of solvent 
on aromatic interactions by Beaut et al. These were quantified by 
1
H NMR 
spectroscopy of bipyridine with the involvement of pendant alkyl and aromatic 
esters. A proportional relationship has been found between the chemical shifts and 
the polarity of the solvent, with the presence of polar solvent in the upfield 
chemical shifts. In DMSO a further reduction of this solvent lead to a minimum 
reduction of the strength of aromatic interactions followed by an increase. Water 
and CDCl3 give similar results, which show that attractive forces of aromatic 
interactions are controlled by the electrostatic forces and non-polar solvent (Fig. 
18). 
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Figure 18: Studying the effect of solvent on the aromatic stacking interactions 
using metal complexes, Δδ = δ (H3 in 59) - δ (H3 in 60) [25]. 
  
Smithrud and Diederich have confirmed that aromatic interactions can be affected 
by solvent. Pyrene complexes with cyclophane in over 15 solvents of different 
polarities have been used to determine the constant and to describe these different 
polarities, an empirical parameter has been used. The relationship between the 
polarity and the stability of these interactions was represented by a line as shown 
below (Fig. 19) 
[25]
. 
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Figure 19: Dependence of the free energy of complexation of the cyclophane 
pyrene complex, −ΔG (kJ mol-1), with solvent polarity, ET(30) (kJ mol-1) [25]. 
 
The importance of this non-covalent interaction refers to its importance in the 
design, control and enhancement of the crystal structure to obtain functional 
properties. For example, modify the behaviour of liquid phase through p-p 
interactions has been achieved by Wech et al, based on arene-perfluoroarene 
interactions. A perfluoroarene has been added to  the moieties of triphenylene, 
that are involved in four compounds, which enhance the stability of liquid 
crystalline mesophase with an increase in the temperature 
[32]
. These interactions 
have also used to form the crystal structure of hexafluorobenzene trans-stillbene, 
which has shown a stacking combination with different orientations and same 
direction (Fig. 20) 
[36]
. However, variation in crystal packing can be obtained by 
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    stacking interactions such as sandwich herringbone, sandwich, gamma (γ) 
and beta (β) packing geometries [21] (Fig. 21). 
 
 
Figure 20: In this crystal structure a combination of stacking interactions is 
involved 
[36]
. 
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a) 5,6-Dichloro-2-(2-fluorophenyl)isoindoline-1,3-dione (beta (β) packing) 
from [openi.nlm.nih.gov]. 
 
 
 
 
b) N,N′-Di-p-tolylethylenediamine (gamma (γ) packing)  
From [openi.nlm.nih.gov]. 
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c) Benzo-fused-1,3,2-dithiazolylium salt (sandwich herringbone). From 
[openi.nlm.nih.gov]. 
 
 
 
 
 
d) Molecules connected by O–H···N and C–H···O inter-molecular hydrogen 
bonds (sandwich) [37]  
Figure 21: a) Beta (β) packing, b) gamma (γ) packing, c) sandwich herringbone 
and d) sandwich geometries.  
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1.4. Supramolecular Chemistry: 
 
In supramolecular chemistry, it has been found that Ar
H
-Ar
F 
synthons, which are 
based on     stacking interactions, are important in controlling the packing of 
crystals. For example, a specific stacking of phenyl-perfluorophenyl has shown an 
increase in reactivity 
[6]
.     Stacking interactions have an essential role in 
forming lots of supramolecular synthons that have importance in various fields. 
For example, supramolecular synthons of naphthalimide rings of one dimer with 
four adjacent dimers have been formed by     stacking interactions [38].  
Also a combination of this stacking has been used between 1,8-napthalimide 
moieties to form four new paddlewheel Cu2(OCR)4(L)2 compounds with unusual 
magnetic properties and highly organized structures, and with possibility of 
unusual physical properties 
[39]
. Zhao et al, have investigated the role of these non-
covalent interactions in forming an infinite stacking of supramolecular synthons 
and have evaluated the different types of stacking between various aromatic rings 
by studying four types of polymeric crystals which have been found in silver 
nitrate as a solvent. These are [R−C≡C− g]n (R=3-pyridyl, 2-pyrazinyl) and 
[Ag2(C≡C−R−C≡C)]n (R=m-C6H4, 2,3-C4H2S), and it has been deduced that the 
assembly of supramolecular synthons is controlled by     stacking interactions, 
which are preferential in multidimensional metal-organic frameworks 
[40]
.  
 
This has been confirmed by Bai et al, who studied three-dimensional helical 
chains, which are Ce(bpdc)2.H2O and Zn(6-bpc)2.H2O, where 6-Hbpc is 2,2`-
bipyridine-6-carboxylic acid, and then reported that the directionality and 
extension of these two supramolecular synthons are controlled by hydrogen 
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bonding and     stacking interactions [37]. It has been shown that, the high 
stability of these supramolecular synthons can be obtained through these non-
covalent interactions, and this has been reported by Santons et al during their 
study the cooperativity between      stacking interactions and H-bonding, 
between 2-[9-(1,3-dithiol-2-ylidene) anthracen-10(9H)-ylidene]-1,3-dithiole and 
C60 based on the donor-acceptor model. It has been found that     stacking 
interactions dominate the structure of these supramolecular synthons, whereas H-
bonding has less contribution for these synthons 
[42]
.  
 
New supramolecular synthons have been synthesised by     stacking 
interactions with various dimensions. First of all, one dimensional synthons such 
as [Cu(phen)(C10H16O4)].3H2O, where phen=1,10phenanthroline 
[43]
, 2-(2-
pyridylamine)pyridinium chloride phosphorous acid 
[44]
, [Mn12O12 
(O2CC6H4C4H3S)16(H2O)3].14CH2CH2 
[45]
, [Zn(NIPH)(py)3]n, [Mn(NIPH(-py)3]n, 
{CO(NIPH)(py)3].(H2O)}n and {[ Cd(NIPH)(im)2.(H2O)].(H2O)}n 
[46]
.  
Secondly, two dimensional synthons such as [Zn(mpdc)Cl2(phen)2] (mpdc=2,6-
dimethylpyridine-3,5-dicarboxylate 
[47]
, [Ag3(tmp)4][CIO4]3.C3H6O, 
[Ag2(tmp)2][C2F5CO2]2, where tmp=2,3,5,6-tetrakis (methylsulfanyl) pyridine 
[48]
, 
2-(2-pyridylamino) pyridinium nitrate monohydrate 
[44]
.  
 Finally, three-dimensional synthons such as {[Zn(bpdc)(H2O)3].3H2O}n 
(H2bpdc=2,2`-Bipyridyl-3,3`-dicarboxylic acid) 
[49]
, {[Ag(4,4`-bpy).H2O](4-
ab).2H2O}, {[Ag2(bpe)2.(tph)].2H2O}, Ag(tbpe)]0.5(4-hb).3H2O} and 
[Ag2(L)2.(tph)] (L¼4,40-bpy or tbpe) 
[50]
, {[Cu3(terephthalate)2(dipyrido[3,2-
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d:2`,3`-f]quinoxaline)2(OH)2]}n, {[Cd2(5,6-diamino-1,10 
phenanthroline)2(terephthalate)2(H2O)2].2H2O}n 
[49]
.  
    stacking interactions have also been used to obtain functional properties. A 
study by Ali-Bouctta et al. showed that     stacking interactions in multiwalled 
carbon nano-tube-doxorubicin supramolecular synthons improved the efficiency 
of carboxic activity as a cancer therapeutic 
[51]
.  
 
Another study confirmed that enhanced stability of an amorphous blue light 
emitter which is 2PPPF, with improved film capacity and a broad emission peak 
resulted from the strong     stacking interactions between its pyrene rings [52]. 
and with an increase in the number of these interactions in the supramolecular 
polymer nanocompesiste enhanced mechanical and healing properties can be 
achieved. In 2007 a major approach in supramolecular chemistry to obtain stable 
complexes through molecular receptors, using only by     stacking 
interactions, which have been used to synthesize a molecular tweezer with two 
corannulene subunits (C60H24) (Fig. 22) with good yield, and the strength of 
these     stacking interactions comes only from the absence of any other 
effects such as polarity or asymmetric atoms 
[53]
. 
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Figure 22: The planar and crystal structures of the molecular tweezer with two 
corannulene subunits (C60H24) 
[53]
. 
 
 
Other supramolecular complexes that have been stabilized by these interactions 
are 2,6-pyridylcarboxylic acid bis-4-pyridylamide, bis (hexafluoro 
acetylacetonate) manganese 
[54]
, 1,3,5-benzonitricarboxylic acid and meta- or 
para- hydroxyl pyridines 
[55]
, side-by-side polyimidazole tripad coils 
[56]
, 
[Cu(butca)0.5(bipy)(H2O)]n.2nH2O, [Zn(H2butca)(phen)(H2O)]n.nH2O and 
[Cd(H2chhca)0.5(phen)(H2O)]n.2nH2O, (H4butca=1,2,3,4-butane tetracarboxylic 
acid, H6chhca=1,2,3,4,5,6-cyclohexanehexacarboxylic acid) 
[57]
. Other self-
assembly supramolecular synthons are bis(μ-7-iodo-8-hydroxyquinoline-5-
sulfonato-k3N,O:O`)bis[triaquanickel(II)]tetrahydrate 
[58]
,dinuclear 
M2Cl4(C13H9N3)2 
[59]
, double-Stranded oligobisnorbornene 
[60]
 and 
[Ln(gly)2(H2O)2(phen)2](ClO4)3 (phen)4 . nH2O [n=0, Ln=Nd]  
[61]
.  
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 Further Applications of Aromatic Stacking Interactions: 
The photodimerisation of olefins in the solid state has been accomplished through 
using these interactions by Coates et al. The crystals of (E)-pentafluorostilbene 
have been formed from the alternated stacking of phenyl and pentafluorophenyl 
rings, and as a result of this a single isomer of the cyclobutane photodimer was 
formed. Also, these stacking interactions have been used to obtain the monomeric 
units for polymerisation by Dougherty. The polymerisation of the diyne lead to 
formation (E)-polybutadiyne (Fig. 23), the (Z)-polymer can be obtained through 
the arrangement of butadiyne units (Fig. 24), and the crystals of stacked phenyl-
pentafluorophenyl with the mixed phenyl-pentafluorophenyl diyne have been 
formed and analysed by XDR. The crystallographic data has shown a head to tail 
arrangement (Fig. 25). 
         
Figure 23: In the solid state, the geometry of stilbene derivative is determined by 
the stacking interactions of phenyl–pentafluorophenyl (a) which lead to formation 
of the stereo-chemical cyclobutane photodimer (b) 
[25]
. 
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Figure 24: (a) Diyne polymerisation to give (E)-polybutadiyne. (b) Butadiyne 
units arrange to form the (Z) polymer 
[25]
.  
 
 
 
 
                      
 
Figure 25: Head-to-tail structure of 1-(2,3,4,5,6-pentafluorophenyl)-4-
phenylbutadiyne 
[25]
. 
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Functional properties of the molecules in the solid state can be achieved by this 
stacking interaction. Crystallographic data that have been collected from the 
engineered crystals of semi-conducting charge transfer complexes such as the 
derivatives of tetracyanoquinone and tetrathiofulvalene have shown that 
controlling all the functional properties can be done by controlling the stacking 
interactions between aromatic rings.  
Edge to face geometry has been measured by Hunter et al; a pair of mutant cycles 
have been built by H-bonded molecular zippers.
1
H NMR using CDCl3 has been 
used to determine the constants of these complexes, the measured energy of the T-
shaped geometry of unfunctionalized aromatic rings was −1.4 ±0.8 kJ mol-1. In 
this study a model structure has been studied by XRD, and the geometry of the 
interaction at the terminus of the zipper. The effect of the substituents has been 
studied through the addition of these different substituents to the two aromatic 
rings that form the T-shaped geometry with both substituents that have low and 
high electron density, and the values that have been obtained from this (Table. 3) 
were in agreement Hammet parameters for X and Y (Fig. 26) and this has been 
represented in the following equation 
[25]
.  
            ΔΔG (π–π) = 5.2 σXσY − 1.9 σX − 1.4 σY −1.5  
 
 
 
 
22 
 
 
 
Substituents Y 
 
 
NO2 
 
Substituent X 
              H 
 
 
NMe2 
NO2 +1.2 −0.2 −1.4 
H −3.4 −1.4 −1.1 
NMe2 −4.6 −1.8 −0.9 
 
Table 3: Substituents with high and low electron density that were added to edge-
to-face rings 
[25]
.   
  
 
 
Figure 26: The terminal edge-to-face aromatic interaction in complex A has been 
determined by using a chemical double mutant cycle. The X-ray crystal structure 
of a model compound which contains the same intermolecular interaction is 
shown in the inset 
[25]
. 
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1.5. Biological Activity: 
 
 
Figure 27: The arene-perfluoroarene interactions in α2D protein [62]. 
 
Zheng and Gao used α2D protein to investigate the role of the strong quadruple 
interaction of the phenyl-perfluorophenyl complex in controlling the direction of 
protein-protein interactions in the liquid phase and found that the stability of this 
protein increased by −1.0 kcal mol-1 due to the electrostatic attractive forces in 
this complex 
[62]
 (Fig. 27). Furthermore, these reactions can be found in the active 
sites on the interface of proteins. Thus it can be used to enhance the catalysis, 
selectivity, folding, and stability of proteins and DNA and the self-assembly of H-
bonding in the biological systems 
[63]
. Yuki et al. made a comparison between the 
original molecular dynamics simulation method with another molecular dynamics 
simulation using a modified sander module with different amino acids such as the 
Trp-cage structure of protein. This showed the importance of      stacking 
interactions in decreasing by half the distance between the root mean square 
deviations in the main and secondary chains. To conclude,     stacking 
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interactions play a key role in the stability of proteins and lead to an increase the 
precision of the data that have been collected by MD simulations 
[64]
.  
Another study by Mao et al. has confirmed that the stability of pigment-protein 
complexes arises because of the     stacking interactions between their 
carotenoids, which also play an important role in folding perdinin-chlorophy11-
protein complexes based on their separation and orientation 
[65]
. This type of 
interaction has also been found in the active site of an aminoglycoside 
phosphotransferase enzyme (APH(3`)-111a) 
[66]
 and the DNA, where     
stacking interactions cannot be ignored in view of their strength during studies of 
their stability.  
 In 2009 a comparison between      and  cation     stacking interactions 
based on the strength of      stacking interactions between nucleobase and 
amino acid using the data of the potential energy that has been scanned from the 
surface of dimers in the crystal structure of DNA-protein complexes showed a 
slight difference of ΔEcorrelation between the protonated histidine and the neutral 
histidine, although there was a remarkable stability in cation     stacking 
interactions in the protonated histidine as a result of the huge increase in ΔEHF 
(Hantree-Fock energy) compared to     stacking interactions in the neutral 
histidine 
[67]
.  
An additional effect of      stacking interactions on the DNA has been shown 
by Mignon et al, who confirmed that the parallel stacking of the     stacking 
interactions affects positively on the efficiency of H-bonding between stacked 
DNA/RNA bases 
[35]
, which also were used by Saha et al. to form the quadruples 
of PNA and DNA 
[68]
. The role of      stacking interactions increases the 
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selectivity of the self-assembly process in the hydrogen-bonded molecular 
capsules has been shown by Tiefenbacher and Rebek (Fig. 28) 
[69]
.  
  
Figure 28: I is an incorporated self-assembly model of benzyl-PD, II represents 
the incorporated self-assembly model of benzyl-PD in both a twisted fashion with 
red colour and horizontally bound to the cavitand with orange colour 
[69]
. 
 
 
1.6. Pharmaceutical Activity: 
 
 
In the pharmaceutical industry the interactions between polyfluoroarene-arene 
synthons have been used widely to design new drugs and enhance the selectivity. 
New drugs can be designed as a result of     stacking interactions. For 
example, a survey by Boehr al et, has shown that, a specific inhibitors of 
aminoglycoside kinases can be achieved by a good knowledge of the nature of 
this type of interaction between Tyr42 and adenine rings of ADP 
[66]
. These 
interactions have also been involved in the drug metabolism of the enzyme such 
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as cytochrome P450 (CYP), and forming the complex of this drug is conditional 
on     stacking interactions, which aim to bind the drug to CYP to form the 
complex 
[64]
. These interactions and the formation of new inhibitors of the human 
enzyme such as CYP2E1 have been investigated by Martikainen et al., who 
reported that      stacking interactions in the active site have an important role 
in affinity folding 
[70]
.  
In 2004 the complexation of these interactions has been used to reduce the 
toxicity of the high concentration of Amitriptyline, which is tricyclic 
antidepressant, through low π-electron density with dinitrobenzenesulfonyl groups 
[71]
. Nawaz et al have confirmed that cation-π and     stacking interactions 
allow the selective inhibition of the enhanced butyrylcholinesterase inhibitors to 
treat  lzheimer’s disease, and this can be achieved using cation-π and      
stacking interactions, which have been found in the active site and lead to improve 
the stability of BCHE complexes 
[72]
. Moreover, it has been shown that the 
function of protein kinase inhibitors can be enhanced by increasing the energies of 
    stacking interactions in the active site between the ligand and the aromatic 
rings 
[73]
, and by increasing the strength of this type of interaction the selectivity 
and low toxicity can be obtained. For example, strong     stacking interactions 
between cyclodextrin with adamantine, and between cyclodextrin with 
adamantine, and between graphene oxide and porphyrin 
[74]
. Furthermore, this 
type of interaction has the ability to interact with caffeine and with various sorts 
of anti-cancer drugs and DNA.  
 
Christianson et al. found that the number of fluorine atoms can contribute to the 
strength of electrostatic interactions in arene-perfluoroarene synthons which make 
it more effective than other interaction forces such as quadruple-quadruple 
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interactions. For example, the high binding affinity of 1,3,4-thiadiazole-2-thione-
based inhibitor of the metalloproteinase stromelysin was achieved through 
electrostatic interactions between Tyr155 and the pentafluorophenyl group in this 
inhibitor (Fig. 29) 
[63]
. 
 
 
 
Figure 29: The electrostatic interactions between Tyr155 and the 
pentafluorophenyl group in 1,3,4-thiadiazole-2-thione-based inhibitor 
[63]
. 
 
 
In this project the new compounds were synthesized using different solvents such 
as THF, DMSO and CH2Cl2, and left at room temperature for different times, then 
rotary evaporation was used to remove the solvents. The products have been 
dissolved in different solvents such as CDCl3 and d6-DMSO to be analyzed by 
NMR, and same solvent to be analyzed by MS, which is methanol. Then the 
product was dissolved in CH2Cl2 and filtered to calculate the product’s yield. 
 Analytical techniques that have been used in this project are nuclear magnetic 
resonance, mass spectrometry, infra-red spectroscopy, and single-crystal X-ray 
Diffraction (XRD). In NMR, all the H nuclei in the different environments were 
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revealed by 
1
H NMR (e.g., 10 H atoms in aromatic rings and one methyl group), 
but F nuclei were revealed by 
19
F NMR (e.g., 4 F atoms in aromatic rings and CF3 
group) and C nuclei by 
13
C NMR (e.g., 9 C atoms in aromatic rings and one CO 
group).  
Functional groups can be introduced by revealing the chemical bonds in the 
compounds using infrared spectroscopy (e.g. one of CN, one of CO and none of 
the OH group). Mass spectrometry has been used to determine the molecular 
mass( e.g. 259;C16H21NO2), and X-ray Diffraction (XRD) can only be used if the 
very pure crystals have been formed to give the data that lead to determine the 
structure of those crystals 
[75]
.  
In this project, 
1
H, 
19
F and 
12
C NMR spectra were performed using a 400 MHz 
spectrometer, using different NMR solvents such as CDCl3 and d6-DMSO. Both 
one and two dimensional NMR spectroscopy have been used, 1D was used to 
detect the chemical shifts and scalar coupling with only a single frequency axis, 
whereas, 2D was used to detect the relationship between the spins of two axis. 
The chemical shifts of 1D NMR spectroscopy have been collected for all the 
prepared compounds, but 2D NMR spectroscopy have been determined only for 
those that gave clear 
13
C NMR spectrum. For example, HMQC and HSQC have 
been used for 1− (4`−bromo, 2, 3, 5, 6−tetrafluorobenzene) −2− methylimidazole 
and 1-(2, 3, 5, 6- tetrafluoropyridyl)-2-methylbenzimidazole 
[76]
.  
The molecular weights for all products were determined using (micro-TOF) mass 
spectrometry. Mass spectral data has been collected mostly in the mass range 
from 50 to 800 m/z, with positive ion polarity, using MeOH for distillation. In 
Infra-red Spectroscopy, identical spectra were obtained from the data that have 
been recorded in the region from 4000 to 400 cm
-1
, using KBr pellets.    
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2.Chapter Two: 
 
 
2.1. Introduction:  
 
All compounds in this project (in chapter 2 and 3) have been prepared under 
similar conditions to those compounds that have been synthesized by Fuji et al, 
(that have been mentioned in chapter 1), which include using solvents such as 
THF and DMSO under room temperature (from 13˚ to 16˚ C), to end up with 
yields from 26 to 83 % with compounds that have imidazole attached in the para 
position compared to the meta position which have yields from 2 to 13 %. In this 
chapter imidazole and prazole and some derivatives have been treated with 
PFB−R then stirred in THF, DMSO or both for different periods of time under 
temperature between RT and 142˚C. The solvent was removed by rotary vacuum 
evaporatoion to give the products, which were analyzed by NMR and IR 
spectroscopy, and mass spectrometry, and then crystallized to be analyzed by 
XRD. The imidazolium salts of these compounds have been prepared in the same 
way as compounds 1 to 25 in this chapter using CH2Cl2 as a solvent.   
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2.2. Materials: 
 
 
2.2.1. Pentafluorobenzene: 
 
  
F
R
F
F
F
F
 
 
Figure 30: Chemical structure of pentafluorobenzene with six-membered ring. 
From [upload.wikimedia.org] and [asd.molfield.org] 
 
The chemical structure of pentafluorobenzene has been shown above (Fig. 30), 
and this compound and some of its derivatives have been used starting materials 
to be treated with imidazole and its derivatives to form compounds containing 
both aryl and polyfluoroaryl groups. These derivatives are 2,3,4,5-
tetrafluorobenzonitrile, 2,3,5,6-tetrafluoropyridine, 2,3,4-trifluorobenzonitrile, 
2,3,5,6-tetrafluorobenzonitrile, octafluorotoluene, 2,4,5-trifluorobenzonitrile, 
2,3,5-trifluoropyridine, 4-bromo-2,3,5,6-tetrafluorobenzotrifluoride 
pentafluorobenzonitile, pentafluoropyridine, octafluorotoluene,  
bromopentafluorobenzene and  pentafluorobenzaldehyde (the importance of these 
compounds has been mentioned in chapter one). 
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2.2.2. Imidazole: 
 
 
 
 
 
 
 
 
Figure 31: Chemical structure of imidazole with five-membered ring 
[77]
 
 
C3H4N2 is the chemical formula of the organic imidazole compound. The 
chemical structure is shown above (Fig. 31), and the first synthesis of this 
compound was in 1858 by Heinrich Debus 
[78]
. Imidazole and some of its 
derivatives have been used as starting materials in this project to react with HFB 
and its derivatives to form form compounds containing both aryl and 
polyfluoroaryl groups, because in Fuji et al, they have reacted easily with the 
derivatives of HFB. Also, they have an essential role in biological and 
pharmaceutical industry, dyestuffs, agrochemicals, and polymer products. For 
example, cis-1-{[4- (1-Imidazolylmethyl) cyclohexyl] methyl} imidazole-succinic 
acid complex has shown inhibitor activity as nonsteroidal aromatase 
[79]
, and 
antifungal imidazole derivative has been investigated as an inhibitor of 
cytochromes P450 by Zhang et al such as 1-(3,5-diaryl-4,5-dihydro-1H-pyrazole-
4-yl)-1H-imidazole derivatives 
[80]
 
[81]
. They have been used  also as antimicrobial 
agents such as 2,4,5-trisubstitued imidazole derivatives 
[82]
 
[83]
, Histidine 
Decarboxylase inhibitors 
[84]
,  anticancer agents such as anti-HIV-1-phenylamino-
1H-imidazole derivatives 
[85]
, antioxidants and selective inhibitors of nNOS 
[86]
, 
antiproliferative agents against melanoma cell lines such as pyrimidin-4-yl-1H-
imidazole derivatives 
[87]
, aromatase inhibitors such as novel indole-imidazole 
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derivatives 
[88]
, tubulin inhibitor such as 4-aryl-5-(3,4,5-trimethoxphenyl)-2-
alkylthio-1H-imidazole derivatives 
[89]
, antibacterial as 2-substitued-4,5-diphenyl-
alkyl imidazole derivatives and inhibitor of CYC enzyme 
[90]
 
[91]
. However, in this 
project, the derivatives of imidazole that have been interacted with PFB and their 
derivatives are 2-, 4-methylimidazole and 2-phenylimidazole compounds. it has 
been shown that methyl group as a substituent lead to increase the strength of 
imidazole, and it has been found that methyl group in the two position of 
imidazole compound provided higher strength of imidazole ring than the methyl 
group in the four position 
[92]
. 
 
2.2.3. Pyrazole: 
 
 
 
 
 
 
 
 
 
                           
Figure 32: The chemical structure of pyrazole 
[93]
 
 
Pyrazole (C3H4N2) has same chemical formula as imidazole, but with different 
positions of nitrogen atoms as shown in the chemical structure above (Fig.32) and 
it with its derivatives have also similar biological activity to imidazole and its 
derivatives. For example, N,N-tetrakis-[(1,5-dimethylpyrazol-3-yl)methyl]-para-
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phenylenediamine,N,Nbis[(3,5-dimethylpyrazol-1-yl)methyl]aniline and N,N-
tetrakis[(3,5-dimethylpyrazol-1-yl)methyl]-para-phenylenediamine have shown 
anticancer and cytotoxicity activity against Hep and P815 cell lines 
[94]
, have been 
used as amine oxidase inhibitors, such as 1-acetyl-3,5-diphenyl-4,5-dihydro-(1H)-
pyrazole derivatives 
[95]
, antimicrobial agents, such as 4-hetarylpyrazole and 
four[2,3-C]pyrazole derivatives 
[96]
 and 3-methyl-4-phenyl-5-(p-
substituedphenyl)-1-(p-sulphamylphenyl)pyrazoles 
[97]
, and have shown antiviral 
activity, such as 5-)4-benzyloxy)phenyl)-3-(4-bromophenyl)-1-thiocarbmethyl-
4,5-dihydro-1H-pyrazole 
[98]
, antitubercular activity such as 3-(4-chlorophenyl)-4-
substitued pyrazole derivatives 
[99]
, antifungal activity, such as 4-(4-bromo-3-aryl-
5-(6,6-dimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-2-yl)-1H-pyrazol-1-yl)-N-
(phenylcarbamothioyl)benzenesulfonamide against Candida albicans 
[100]
, and are 
antimalarial agents, such as 3-phenyl-1-(4-methylphenyl-1H-pyrazole-4-
carboxylic acid(147-ftp), analgesic agents such as 1,2,4-triazole and benzoxazoles   
[101]
, telomerase inhibitors, such as novel aryl-2H-pyrazole derivatives 
[102]
, and 
antibacterial agents such as 1,3-diaryl pyrazole derivatives bearing rhodanine-3-
fatty acid moieties 
[103]
. 
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Comp 
or salt 
no. 
Chemical reactions 
1 
N
H
F
F
F
F
+
NH N
H
F
F
F
N
N
N
RT
THF
 
2 
NH N
+
N
F
H
F
FF
NF
FF
N
N
H
THF
RT
 
3 
NH N
+
F
F
H
HF
N
F
H
N
N
H
F
N
THF
RT
 
4 
NH N
+
F
H
F
FF
N
F
FF
N
N
H
N
THF
RT
 
5 
NH N
+
N
F
H
F
HF
NH
F
N
N
H
F
THF
RT
 
 
 
 
6 
NH N
+
H
F
F
HF
N
F
F
N
N
H
H
N
THF
RT
 
 
 
7 
NH N
+
F
CF3
F
FF
F
F
F
N
N
F
F3C
F
THF
RT
 
8 
F
Br
F
F F
F
F
F
NH N
Br
F
F
F
N
NF
F
F
+
Br
F F
F
F
F
FN
N
+
THF

 
9 
CN
F
FF
F
F
+NH N
CH3
N N
NC
CH3
F
F
F
F
THF
RT
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10 
N
F
F
F
FF
+
N
N N
CH3
F
F
F
F
NH
N
CH3
RT
THF
 
11 NH N
CH3
+
F
CF3
F
FF
F
F
F
N
N
F
F3C
F
CH3
THF
RT
 
12 
F
F
F F
F
Br
NH N
Me
+
DMSO
Br
F
F
F
F
N
N
Me
THF/
 
13 
F
FF
F
F
CN
+
NH N
CH3
THF
RT N N
F
F
F
F
CH3
NC
 
14 +
N
F
F
F F
F
NH N
CH3
N
N
N
CH3
F F
FF
THF
RT
 
15 
NH N
CH3
+
F
CF3
F
FF
F
F
F
N
N
F
F3C
F
CH3
THF
RT
 
16 
Br
F
F
F
F
F
NH N
Me
+
DMSO
N
N
CH3
Br
F
F
F
F
THF/
 
17 
F
F
F
F
F
H
NH N
Me
F
F
F
H
F
N
N
Me
F
H
F
F F
N
N
Me
DMSO
 +/KOH
 
18 
NH N
Me
F
F
F
I
N
NF
Me
+
F
F
F
F F
I

DMSO
/THF
 
19 
 
CN
F
F
F
F
F
+
THF
NH N
Ph
NC
F
F
F
F
N
N
Ph

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20 
CHO
F
F
F
F
F
+ THF
NH N
Ph
N N
OHC
Ph
F
F
F
F

 
21 
N
F
F
F
F
F
+ N
N N
Ph
F
F
F
F
NH
N
Ph
RT
THF
 
22 
N
N
H
F
F
F
CN
F F
N
N
NC
F
F
F
F
THF

 
23 
N
F
F
F
FF
+
N
N
N
F
F
F
F
CH3
CH3
N
NH
CH3
CH3
RT
THF
 
 
24 
N
NH
CH3
CH3
+
F
F
F
CN
F
F
N
N
NC
CH3
CH3
F F
FF
THF

 
25 
N
F
F
F
FF
+ NH
N
THF
N
N
N
F
F
F
F
RT
 
26 
F
F
F
F N
N
Br
CH3
+
Br
F
F
F
F
N
N
Me
Br
+
Br
-
RT
CH2CL2
 
27 
F
F
F
F N
N Me
N
+
Br
F
F
F
F
N
N
Me
N
+
Br
-
RT
CH
2
Cl
2
 
28 
F
F
H
F N
N
N
+
Br
F
H
F
F
N
N
N
+
Br
-
RT
CH
2
Cl
2
 
29 
N
F
F
F
F N
N
CH3
+
Br N
F
F
F
F
N
N
Br
-
 Me
+RT
CH2CL2
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30 
F
F
F
F N
N
Br
CH3
+
Br
F
F
F
F
NN
BrBr
-
 Me
+RT
CH2CL2
 
31 
F
F
F
F N
N
F3C
+
Br
F
F
F
F
N
N
+
F3C
Br
-
 H
CH2CL2
RT
 
32 
F
F
F
F N
N
F3C
CH3
+
Br
F F
FF
N
N
+ CF3
CH3
Br
-
CH2CL2
RT
 
33 +
N
F
F
F
F N
N
Me
CH3I
F
N
F
F
F
N
N
Me
Me
+
I
-
RT
CH
2
Cl
2
 
34 
N
F
F
F
F N
N CH3
+
Br
N
FF
F F
N
N
+
CH3
Br
-
CH2CL2
RT
 
 
Table 4: Chemical reactions of PFB-R with imidazole, pyrazole and their 
derivatives, and the chemical reactions of these compounds to form imidazolium 
salts. 
 
The treatment of 2,3,4,5-tetrafluorobenzonitrile, 2,3,5-trifluoropyridine and 4-
bromo-2,3,5,6-tetrafluorobenzotrifluoride separately with imidazole afforded the 
compounds: 1-(2,3,6-trifluorobenzonitrile)imidazole (1), 1-
(heptafluorotolyl)imidazole (7), and a mixture of 1-(5-bromo-3,4,6-
trifluorobenzotrifluoride)imidazole (8a), and 1-(6-bromo-3,4,5-
trifluorobenzotrifluoride)imidazole (8b) respectively. But the treatment of 
imidazole with 2,3,5,6-tetrafluoropyridine, 2,3,4-trifluorobenzonitrile, 2,3,5,6-
tetrafluorobenzonitrile, octafluorotoluene and 2,4,5-trifluorobenzonitrile 
separately is expected to afford 1-(3,4,6-trifluoropyridyl)imidazole (2), 1-(2,3-
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difluorobenzonitrile)imidazole (3), 1-(3,4,6-trifluorobenzonitrile)imidazole (4), 1-
(4,6-difluoropyridyl)imidazole (5) and 1-(3,6-difluorobenzonitrile)imidazole (6) 
respectively. 
 
The compounds 1-(2,3,5,6-tetrafluorobenzonitrile)-2-methylimidazole (9), 1-
(2,3,5,6-tetrafluoropyridyl)-2-methylimidazole (10), 1-(heptafluorotolyl)-2-
methylimidazole (11) and 1-(4-bromo-2,3,5,6-tetrafluorobenzyl)-2-
methylimidazole (12) were formed through the treatment of 2-methylimidazole 
with each of  pentafluorobenzonitile, pentafluoropyridine, octafluorotoluene and  
bromopentafluorobenzene respectively, which, plus pentafluorobenzene and 
iodopentafluorobnezene, also have been treated with 4-methylimidazole to afford 
1-(2,3,5,6-tetrafluorobenzonitrile)-4-methylimidazole (13), 1-(2,3,5,6-
tetrafluoropyridyl)-4-methylimidazole (14), 1-(heptafluorotolyl)-4-
methylimidazole (15), 1-(4-bromo-2,3,5,6-tetrafluorobenzyl)-4-methylimidazole 
(16), 1-(2,3,5,6-tetrafluorobenzyl)-4-methylimidazole (17a & 17b) and 1-(4-iodo-
2,3,5,6-tetrafluorobenzyl)-4-methylimidazole (18).  
The compounds that have been afforded through the reaction of 2-
phenylimidazole with pentafluorobenzonitile, pentafluorobenzaldehyde and 
pentafluoropyridine are 1-(2,3,5,6-tetrafluorobenzonitrile)-2-phenylimidazole 
(19), 1-(2,3,5,6-tetrafluorobenzaldehyde)-2-phenylimidazole (20) and 1-(2,3,5,6-
tetrafluoropyridyl)-2-phenylimidazole (21). The treatment of pyrazole with 
pentafluorobenzonitile lead to the formation of 1-(2,3,5,6-tetrafluorobenzonitrile) 
pyrazole (22), which also has been treated with 3,5-dimethylpyrazole to form 1-
(2,3,5,6-tetrafluorobenzonitrile)-3,5-dimethylpyrazole (23), whereas, replacing 
pentafluorobenzonitile with pentafluoropyridine afforded 1-(2,3,5,6-
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tetrafluoropyridyl)-3,5-dimethylpyrazole (24). An attempt to synthesize 1-
(2,3,5,6-tetrafluoropyridyl)pyrazole (25) was made through the treatment of 
pyrazole with pentafluoropyridine in THF at RT. 
However, the treatment of benzyl bromide with the compounds 16, 13, 1, 10, 12, 
7 and 15 in CH2Cl2 lead to synthesis the imidazulium salts 1-(4-bromo-2,3,5,6-
tetrafluorobenzyl)-3-benzyl-4-methylimidazolium bromide (26), 1-(2,3,5,6-
tetrafluorobenzonitrile)-3-benzyl-4-methylimidazolium bromide (27), 1-(2,3,6-
trifluorobenzonitrile)-3-benzyl-imidazolium bromide (28), 1-(2,3,5,6-
tetrafluoropyridyl)-3-benzyl-2-methylimidazolium bromide (29), 1-(4-bromo-
2,3,5,6-tetrafluorobenzyl)-3-benzyl-2-methylimidazolium bromide (30), Synthesis 
1-(heptafluorotolyl)-3-benzyleimidazolium bromide (31) and 1-(heptafluorotolyl)-
3-benzyl-4-methylimidazolium bromide (32) respectively. In contrast, compound 
14 has not only been treated with benzyl bromide but also with methyl iodide to 
form 1-(2,3,5,6-tetrafluoropyridyl)-3-benzyl-4-methylimidazolium bromide (33) 
and 1-(2,3,5,6-tetrafluoropyridyl)-3,4-dimethylimidazolium iodide (34). 
2.2. Preparation: 
 
All reactions were performed by stirring the starting materials in THF at room 
temperature (with yields between 36% and 102%), except 8, 12, 16, 17, 18 and all 
salts from 26 to 34. All salts have been formed in CH2Cl2 at RT (yields between 
48% and 113%), and compounds 8, 12, 16, 17 and 18 were formed under 
temperature from 60˚C to 142˚C in a mixture of DMSO and THF with yields 
between 30% and 110%, except 17 which was formed by heating at 55˚C for three 
hours in DMSO with KOH as a base and yield 29%.  
40 
 
Some compounds have been synthesized by further steps than other compounds, 
such as compound 12, which has been afforded by the treatment of 
2−methylimidazole with 4−bromopentafluorobenzene in THF and DMSO, and 
then this mixture has been heated for three hours at 55˚C. After the reaction 
mixture was poured into 500 ml of cold water, a white solid was deposited. Then 
it was collected and dissolved in 100 ml of CH2Cl2 with adding magnesium 
sulfate. The mixture was filtered; a white solid was obtained after evaporation 
under reduced pressure. The same steps in this reaction have been done again in 
the reactions of compounds 16, 17 & 18, but with different amount of distilled 
water, in which, 500 ml of water was used with compounds 12 & 16, 300 ml with 
compound 17, and 120 ml of water with compound 18. 
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2.3. Characterization: 
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Figure 33: The labels that have been used to represent the NMR data of 
imidazole, pyrazole compounds and imidazolium salts (R = Br, I, F. R
1
, R
2
 = H, 
CH3. R1, R2, R3 = H, F). 
 
All compounds and salts have been characterized by mass spectrometry (MS) and 
NMR spectroscopy. In MS, all compounds ([M + H]
+
) and salts ([M ]
+
) gave the 
expected peak. For example, 1 and 2 show peaks at 224, 3 and 6 at 206, 8 and 27 
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at 346, 9 and 13 at 256, 10 and 14 at 232, 11 and 15 at 299, 12 and 16 at 308, 23 
and 33 at 246, 26 and 30 at 400, 29 and 34 at 322 m/z. Two multiplet or quartet 
peaks are exhibited in the 
19
F NMR spectra for all compounds and salts at 
resonances ca. δ −86 and δ −149 ppm, except for 1, 2, 4, 5, 6, 7, 8, 11, 15, 17 and 
28 which have three peaks. The third peak is assigned to the CF3 group (δ −55 to 
−56 ppm) or to one fluorine atom in a different environment. The 1H NMR 
spectrum of compound 35 shows a mixture of the expected product and 
unidentified compounds. All the hydrogen atoms that are attached directly to the 
imidazole or pyrazole ring resonate at δ 6−8 ppm, whereas in the salts, these 
hydrogen atoms resonate from δ 7 to 11 ppm. The 1H NMR spectra possess a 
resonance from δ 2.36 to 2.62 ppm characteristic of the three hydrogen atoms of 
the 2-methyl group (bonded to the carbon atom between the two nitrogen atoms) 
in compounds 9 to 12 and salts 29 and 30, whereas compounds 13 to 18 with their 
imidazolium salts (26, 27, 32, 33, 34) which have a 4-methyl group display a 
lower resonance δ 2.12 to 3.35 ppm. In salt 33 there are other three hydrogen 
atoms in the methyl group that are bonded directly to the nitrogen atom at the 3 
position of the imidazole ring which resonate at δ 5.31 ppm. The CH2 group that 
is attached directly to nitrogen atom and phenyl ring in the imidazolium salts 
gives a single peak at the resonance of δ 5 ppm.  
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The 
13
C NMR spectra have been recorded for compounds 12 and 18, the six 
carbon atoms of the benzyl ring in both compounds have shown multiple peaks at 
the resonances between δ 73 and 147 ppm, whereas, δ 116 to 145 are the 
resonances of the peaks of the three carbon atom in imidazole ring, and the carbon 
atom of 2− and 4−methyl group in both 12 and 18 give single resonances δ 31 
ppm. Moreover, for 12 and 18, the data of two dimensional NMR spectrum 
(HSQC and HMBC) have been collected are consistent with the chemical 
structures of 12 and 18. For 12, the HSQC spectrum shows that H−2` correlates 
with C−2`, H−4 correlates with C−4, H−5 correlates with C−5 (Fig. 34). The 
HMBC spectrum shows that H−2` correlates with C−2`and C−2 and H−4 
correlates with C−2, C−4, C−5 and H−5 correlates with C−2, C−4 and C−5 (Fig. 
35). For 18, the HSQC spectrum shows that H−4` correlates with C−4`, H− 2 
correlates with C−2, H−5 correlates with C−5 (Fig. 36). The HMBC spectrum 
shows that H−4` correlates with C−4`, C−4 and C−2, H−2 correlates with C−2, 
C−4 and C−5, H−5 correlates with C−2, C−4 and C−5 (Fig. 37).  
The NMR data for the expected compounds 1-(3,4,6-trifluoropyridyl)imidazole 
(2), 1-(2,3-difluorobenzonitrile)imidazole (3), 1-(3,4,6-
trifluorobenzonitrile)imidazole (4), 1-(4,6-difluoropyridyl)imidazole (5), 1-(3,6-
difluorobenzonitrile)imidazole (6) show slow formation of the products, which 
need months to reach completion as shown in Figures 38, 39, 40, 41 and 42. 
Compounds and salts 1, 12, 14, 16, 18, 19, 16, 30 and 34 have been analyzed by 
IR spectroscopy, which shows the expected peaks for all these compounds. 
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Figure 34: The HSQC spectrum of 1-(4-bromo-2,3,5,6-tetrafluorobenzyl)-2-methylimidazole 12. 
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Figure 35: The HMBC spectrum of 1-(4-bromo-2,3,5,6-tetrafluorobenzyl)-2-methylimidazole 12.
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Figure 36: The HSQC spectrum of 1-(4-iodo-2,3,5,6-tetrafluorobenzyl)-4-methylimidazole 18. 
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Figure 37: The HMBC spectrum of 1-(4-iodo-2,3,5,6-tetrafluorobenzyl)-4-methylimidazole 18.  
48 
 
 
Figure 38: The formation of the expected compound 1-(3,4,6-trifluoropyridyle)imidazole 2 over months starting from green to blue. 
 
49 
 
 
Figure 39: The formation of the expected compound 1-(2,3-difluorobenzonitrile)imidazole 3 over months starting from green to blue. 
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Figure 40: The formation of the expected compound 1-(3,4,6-trifluorobenzonitrile)imidazole 4 over months starting from green to blue. 
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Figure 41: The formation of the expected compound 1-(4,6-difluoropyridyle)imidazole 5 over months starting from green to blue.
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Figure 42: The formation of the expected compound 1-(3,6-difluorobenzonitrile)imidazole 6 over months starting from green to blue.
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Crystallization of all the compounds was attempted by slow evaporation of the 
solution of these compounds in MeOH at room temperature, and this 
crystallization led to increase the purity of all the compounds but without giving 
the desired single crystals suitable to be analyzed by XRD, except salts 26 (Fig. 
43) and 34 (Fig. 44), which gave colourless and brown crystals respectively. 
Single crystal X-ray diffraction studies show monoclinic crystal system with face 
to face geometry as a result of alternating stacking between polyfluoroaryl and 
aryl groups (Fig. 45&46). The crystals are in different space groups (I2/a in 26 
and P21/c in 34), centroid−centroid distance (Dcent = 4.647 Å in 26 and Dcent = 
3.638 Å in 34), angle (ϕ = 14.14˚ in 26 and ϕ = 9.35˚ in 34), the hinge angle 
(C11−C10−N2) is α = 111.17˚ in 26 and α = 111.57˚ in 34. The stack shift was s = 
0.00 Å in both (Fig. 47&48) (Crystallographic data for 26 and 34 has been shown 
in table 9 and table 10 respectively in chapter 5).  
The columnar stacking in these crystals has been prevented by ions and the tick-
shaped cations, and the planes of the complementary rings in both cannot be 
parallel. Further views of these crystals have been shown in figures 49 and 50. 
These two salts have the same structure with difference only in the nature of the 
fluoroaryl ring. Selected bond length (Å) and bond and torsion angles (˚) for salts 
26 and 34, except those which relate to C17, Br2 and N3 atoms are given in Table 
5, and those which relate to C17, Br2 and N3 atoms have been shown in Table 6. 
All bonds lengths between two atoms in 26 were almost identical to those of 34, 
except the bonds length that were in fluoroaryl ring, which were attached (one to 
two bonds away) to the bromide atom in 26 or nitrogen atom in 34, and these 
bonds are N3 C7 1.302(4) Å, N3 C8 1.306(4) Å, Br2 C17 1.881(3) Å, C17 C7 
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1.388(4) Å and C17 C8 1.382(4) Å. Identical angles to those of 26 are observed in 
34, and the range of these angles was from 106.3(2) of C2 C3 N2 to 131.8(3) of 
C2 C3 C4 in 26 and from 106.6(2) of C2 C3 N2 to 130.1(3) of C2 C3 C4 in 34, 
except angles that are involved C17, Br2, and N3 atoms. The torsion angles in 
both 26 and 34 are similar. The experimental errors in 26 were almost similar to 
those of 34. Hydrogen bonding between the bromide anion and acidic hydrogen 
H1 is suggested based on the distance between Br∙∙∙∙C1, which is 3.485 Å in 26 
and 3.453 Å in 34. Weaker interactions are suggested between the other hydrogen 
atom of the imidazolium ring and the bromide anion, which were C3∙∙∙Br 3.584 Å 
in 26 and 3.683 Å in 34. 
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Figure 43: Structure of 1-(4-bromo-2,3,5,6-tetrafluorobenzyle)-3-benzyl-4-
methylimidazolium bromide 26. 
 
Figure 44: The structure of 1-(2,3,5,6-tetrafluoropyridyl)-3-benzyl-4-
methylimidazolium bromide 34.   
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Salt 26 Salt 34 
F6 C6 1.336(3) 1.344(3) 
F7 C7 1.347(3) 1.340(3) 
F8 C8 1.346(3) 1.339(4) 
F9 C9 1.343(3) 1.338(3) 
N1 C1 1.331(4) 1.336(3) 
N1 C2 1.390(4) 1.386(3) 
N1 C5 1.421(4) 1.420(3) 
N2 C1 1.321(4) 1.320(3) 
N2 C3 1.389(4) 1.390(4) 
N2 C10 1.469(3) 1.483(3) 
C2 C3 1.352(4) 1.348(4) 
C3 C4 1.488(4) 1.484(4) 
C5 C6 1.384(4) 1.374(4) 
C5 C9 1.383(4) 1.379(4) 
C6 C7 1.374(4) 1.377(4) 
C8 C9 1.377(4) 1.381(4) 
C10 C11 1.517(4) 1.517(4) 
C11 C16 1.394(4) 1.385(4) 
C11 C12 1.378(4) 1.394(4) 
C12 C13 1.397(4) 1.393(4) 
C13 C14 1.384(5) 1.379(4) 
C14 C15 1.380(5) 1.383(5) 
C15 C16 1.392(4) 1.393(4) 
   
C1 N1 C2 109.4(2) 109.1(2) 
C1 N1 C5 123.5(2) 124.1(2) 
C2 N1 C5 127.0(2) 126.7(2) 
C1 N2 C3 110.0(2) 109.6(2) 
C1 N2 C10 124.1(2) 122.7(2) 
C3 N2 C10 125.8(2) 127.7(2) 
N2 C1 N1 107.7(2) 107.8(2) 
C3 C2 N1 106.7(2) 106.8(2) 
C2 C3 N2 106.3(2) 106.6(2) 
C2 C3 C4 131.8(3) 130.1(3) 
N2 C3 C4 121.8(2) 123.2(3) 
C6 C5 C9 118.4(3) 117.8(3) 
C6 C5 N1 121.0(3) 121.2(3) 
C9 C5 N1 120.5(2) 121.0(3) 
F6 C6 C5 119.8(3) 120.9(3) 
F6 C6 C7 119.6(3) 120.4(3) 
C5 C6 C7 120.6(3) 118.7(3) 
F7 C7 C6 118.8(2) 119.2(3) 
F8 C8 C9 118.7(2) 118.6(3) 
F9 C9 C5 119.5(2) 120.8(3) 
F9 C9 C8 119.8(2) 121.0(3) 
C5 C9 C8 120.7(3) 118.2(3) 
N2 C10 C11 111.2(2) 111.6(2) 
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C16 C11 C12 119.0(3) 119.1(3) 
C16 C11 C10 120.9(3) 121.7(3) 
C12 C11 C10 120.1(2) 119.2(3) 
C13 C12 C11 120.6(3) 120.5(3) 
C14 C13 C12 120.0(3) 120.1(3) 
C13 C14 C15 119.9(3) 119.5(3) 
C14 C15 C16 119.9(3) 120.8(3) 
C11 C16 C15 120.6(3) 120.0(3) 
   
C3 N2 C1 N1 -0.8(3) 0.7(3) 
C10 N2 C1 N1 175.2(2) -179.7(2) 
C2 N1 C1 N2 0.9(3) -0.6(3) 
C5 N1 C1 N2 -174.7(2) 177.4(2) 
C1 N1 C2 C3 -0.7(3) 0.2(3) 
C5 N1 C2 C3 174.7(3) -177.7(3) 
N1 C2 C3 N2 0.2(3) 0.2(3) 
N1 C2 C3 C4 177.9(3) -177.6(3) 
C1 N2 C3 C2 0.4(3) -0.5(3) 
C10 N2 C3 C2 -175.6(2) 179.9(2) 
C1 N2 C3 C4 -177.6(2) 177.5(3) 
C10 N2 C3 C4 6.5(4) -2.1(4) 
C1 N1 C5 C6 -63.6(4) 61.5(4) 
C2 N1 C5 C6 121.7(3) -120.8(3) 
C1 N1 C5 C9 113.7(3) -119.0(3) 
C2 N1 C5 C9 -61.1(4) 58.6(4) 
C9 C5 C6 F6 178.7(2) -178.4(2) 
N1 C5 C6 F6 -4.1(4) 1.1(4) 
C9 C5 C6 C7 -1.1(4) -0.1(4) 
N1 C5 C6 C7 176.1(2) 179.4(3) 
F6 C6 C7 F7 0.7(3) -1.8(4) 
C5 C6 C7 F7 -179.5(2) 179.9(3) 
C6 C5 C9 F9 -180.0(2) 179.0(2) 
N1 C5 C9 F9 2.8(4) -0.4(4) 
C6 C5 C9 C8 0.9(4) -0.5(4) 
N1 C5 C9 C8 -176.4(3) -179.9(2) 
F8 C8 C9 F9 0.4(4) 0.9(4) 
F8 C8 C9 C5 179.6(3) -179.6(3) 
C1 N2 C10 C11 -100.7(3) 87.1(3) 
C3 N2 C10 C11 74.7(3) -93.4(3) 
N2 C10 C11 C16 38.9(4) 103.0(3) 
N2 C10 C11 C12 -143.2(3) -76.9(3) 
C16 C11 C12 C13 0.2(5) -0.7(4) 
C10 C11 C12 C13 -177.8(3) 179.2(3) 
C11 C12 C13 C14 -0.5(5) -0.1(4) 
C12 C13 C14 C15 0.3(5) 0.8(5) 
C13 C14 C15 C16 0.4(5) -0.5(5) 
C12 C11 C16 C15 0.4(5) 0.9(5) 
C10 C11 C16 C15 178.3(3) -179.0(3) 
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C14 C15 C16 C11 -0.7(5) -0.3(5) 
 
Table 5: Selected bond lengths (Å) and bond and torsion angles (˚) for salts 26 
and 34, except those related to C17, Br2 and N3. 
 
Salt 26 Salt 34 
Br2 C17 1.881(3) N3 C7 1.302(4) 
C17 C7 1.388(4) N3 C8 1.306(4) 
C17 C8 1.382(4)  
  
C17 C8 F8 120.2(3) C7 N3 C8 117.5(3) 
C8 C17 C7 117.8(3) N3 C7 F7 117.0(3) 
C8 C17 Br2 121.6(2) N3 C7 C6 123.8(3) 
C7 C17 Br2 120.6(2) N3 C8 F8 117.4(3) 
F7 C7 C17 120.0(3) N3 C8 C9 124.0(3) 
C6 C7 C17 121.3(3)  
  
C7 C17 C8 C9  -0.6(4) C8 N3 C7 F7 179.7(3) 
Br2 C17 C8 C9 179.4(2) C8 N3 C7 C6 -1.3(5) 
C7 C17 C8 F8 179.8(2) F6 C6 C7 N3 179.3(3) 
Br2 C17 C8 F8 -0.2(4) C5 C6 C7 N3 1.0(5) 
C8 C17 C7 F7 -179.6(2) C7 N3 C8 F8 -179.5(3) 
Br2 C17 C7 F7 0.4(3) C7 N3 C8 C9 0.7(5) 
C8 C17 C7 C6 0.3(4) N3 C8 C9 F9 -179.3(3) 
Br2 C17 C7 C6 -179.69(19) N3 C8 C9 C5 0.2(5) 
C17 C7 C6 F6-179.2(2) C8 N3 C7 F7 179.7(3) 
C17 C7 C6 C5 0.6(4)  
F9 C9 C8 C17 -179.2(3)  
C5 C9 C8 C17 0.0(4)  
 
Table 6: Selected bond lengths (Å) and bond and torsion angles (˚) for salts 26 
and 34 that related to C17, Br2 and N3. 
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Figure 45: The monoclinic crystal system of 1-(4-bromo-2,3,5,6-
tetrafluorobenzyle)-3-benzyl-4-methylimidazolium bromide 26. 
 
 
Figure 46: The monoclinic crystal system of 1-(2,3,5,6-tetrafluoropyridyl)-3-
benzyl-4-methylimidazolium bromide 34.   
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Figure 47: The π-π stacking of 1-(4-bromo-2,3,5,6-tetrafluorobenzyle)-3-benzyl-
4-methylimidazolium bromide 26. 
 
 
Figure 48: The π-π stacking of 1-(2,3,5,6-tetrafluoropyridyl)-3-benzyl-4-
methylimidazolium bromide 34.  
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Figure 49: The crystal packing of 1-(4-bromo-2,3,5,6-tetrafluorobenzyle)-3-
benzyl-4-methylimidazolium bromide 26 viewed along the b axis.   
 
 
 
A
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B 
Figure 50: A & B The crystal packing of 1-(2,3,5,6-tetrafluoropyridyl)-3-benzyl-
4-methylimidazolium bromide viewed along different axes.   
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3.Chapter Three: 
 
 
3.1. Introduction: 
 
The compounds and salts in this chapter were prepared similarly to those in 
chapter 2. Benzimidazole derivatives were dissolved in THF, then added to 
pentafluorobenzene derivatives, and left for different periods of time at room 
temperature. The solvent was then evaporated under reduced pressure. An NMR 
sample was prepared by adding CDCL3, d6-DMSO or both, to be analysed by 
1
H 
and 
19
F NMR. Another sample was dissolved in MeOH to be analysed by MS. 
After the desired product was confirmed by these two analytical methods, the 
product was dissolved in CH2Cl2 and filtered, then the solvent has been removed 
by rotary evaporation and the product’s yield was calculated. To crystalize the 
product, a small amount was dissolved in MeOH the solution left to evaporate 
slowly in air at ambient temperature. Salt 44 was achieved in the same way, using 
CH2CL2 as a solvent.  
 
3.2. Materials: 
 
3.2.1. Pentafluorobenzene: 
 
Pentafluorobenzene and its derivatives that were treated with imidazole, pyrazole 
and their derivatives in chapter 2 were also studied for their reaction with 
benzimidazole and its derivatives and indazole. These compounds are 
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tetrafluorophathalonitrile, pentafluorobenzaldehyde, chloro-tetrafluoropyridine, 
pentafluoropyridine, and octafluorotoluene. The chemical structure and the 
importance of pentafluorobenzene and its derivatives have been mentioned in 
chapters 1 and 2.  
 
3.2.2. Benzimidazole: 
 
  
 
Figure 51: The chemical structure of benzimidazole 
[104]
.  
 
Benzimidazole (C7H6N2) was synthesized through the addition of a benzene ring 
to the carbon numbers 4 and 5 of the imidazole ring to give a product with a 
higher boiling and melting point than the starting materials 
[92]
. In this project, 
benzimidazole and its derivatives were reacted with HFB and their derivatives, 
which have been used in the biological activity and possible use in the 
pharmaceutical industries. For instance, they have antiviral activity, such as 1-
substituted-2-[(benzotriazol-1/2-yl) methyl] benzimidazole 
[105]
 and 2-
phenylbenzimidazole derivatives 
[106]
, antiparasitic activity, such as 2-
(trifluoromethyl)-benzimidazole derivatives 
[107]
, antimicrobial character, such as 
2-alkylsulfanyl derivatives of 5-methylbenzimidazole 
[108]
, novel benzimidazole-
hydrazone derivatives 
[109]
 and tetrahydronaphthalene benzimidazole derivatives 
[110]
, antiprotozoal properties, such as dicationic biphenyl benzimidazole 
derivatives 
[111]
 and as JNK3 inhibitors, such as 1,2-diaryl-1H-benzimidazole 
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derivatives (JNK3=c-Jan N-terminal kinases), which have been used to treat 
neurodegenerative diseases such as  lzheimer’s, Parkinson’s and ischemic injury 
[112]
. 
 
3.2.3. Indazole:
 
  
 
                              
Figure 52: The chemical structure of indazole compound 
[113]
. 
 
Indazole has the same chemical formula as benzimidazole (C7H6N2) (Fig.52), but 
with a different position of the nitrogen atoms. Indazole and its derivatives have 
pharmaceutical and biological uses. For example, 4,5,6,7-tetrahydro-2H-indazole 
derivatives show anti-inflammatory activity 
[114]
, 3-cyano-2-(4-nitrophenyl)-2H-
indazole N1-oxide and 2-(4-chlorophenyl)-3-cyano-2H-indazole N1-Oxide have 
antiepimastigote activity and anti-T. cruzi activity with low cytotoxicity 
[115]
. 3-
[(N-carboalkoxy)ethylamino]-indazole-dione derivatives show inhibitor activity 
of the human carbonyl reductase 
[68]
, antifungal and antibacterial activity, such as 
4,6-diphenyl-4,5-dihydro-3-hydroxy-2[H] indazole 
[116]
. 4-(trifluoromethyl)-1H-
indazole has shown activity against H460, A549, OS-RC-2, Lovo.HepG2, Bel-
7402, SGC-7901 and MDA-MB-231 cancer cell lines 
[117]
, and as antichagasic 
drug, such as 1,2-disubstituted 5-nitroindazolinones 
[118]
.  
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Benzimidazole was treated with tetrafluorophathalonitrile, 
pentafluorobenzaldehyde, chloro-tetrafluoropyridine, pentafluoropyridine,  and 
octafluorotoluene to afford 1-(2,3,6-trifluorophathalonitrile)benzimidazole (35), 
1-(2,3,5,6-tetrafluorobenzaldehyde)benzimidazole (36), 1-(6-chloro-2,3,5-
trifluoropyridyl)benzimidazole (37), 1-(2,3,5,6-tetrafluoropyridyl)benzimidazole 
(38) and 1-(heptafluorotolyl)benzimidazole (39) respectively. Octafluorotoluene, 
pentafluorobenzonitrile and pentafluoropyridine were treated with 2-
methylbenzimidazole to give 1-(heptafluorotolyl)-2-methylbenzimidazole (40), 1-
(2,3,5,6-tetrafluorobenzonitrile)-2-methylbenzimidazole (41) and 1-(2,3,5,6-
tetrafluoropyridyl)-2-methylbenzimidazole (42). An attempt to synthesis 1-
(2,3,5,6-tetrafluoropyridyl)indazole (43) in THF at RT was unsuccessful. A 
benzimidazolium salt 1-(2,3,5,6-tetrafluoropyridyl)-3-benzyl-benzimidazolium 
bromide (44) was afforded by the reaction of benzyl bromide with compound 38. 
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THF
RT
 
41 F
F
CNF
F
F
+
N
NH
CH3
N
N
CH3
F
F
CNF
F
RT
THF
 
42 
N
F
F
F
F
F
+
N
F
F
F
F
N
N
CH3
NH
N
CH3
THF
RT
 
43 
NNH
+
N
F
F
F
FF
RT
THF
N
N
NF
F
F
F  
44 
N
N
N F
FF
F
+ Br
N
N
N
F
F
F
F
Ph
HBr
+
CH2CL2
RT
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Table 7: Chemical reactions of PFB-R with benzimidazole, indazole and their 
derivatives, and the chemical reactions of these compounds to form 
benzimidazolium salts. 
 
3.3. Synthesis: 
 
Compounds 35 to 43 were synthesized in THF at ambient temperature. The salt 44 
was synthesized under room temperature in CH2Cl2 with yield of 67 %.  
 
3.4. Characterization:
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Figure 53: The labels that have been used to represent the NMR data of 
benzimidazole compounds and their salts. (R1= F, CF3, CN, CHO, R2= F, CN, R= 
F,Cl and R
1
= H, CH3). 
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The mass spectra of all the compounds and exhibit the expected [M + H]
+
 or [M]
+
 
peaks). The 
19
F NMR spectra of all these compounds are similar to those of the 
compounds in the second chapter (compounds and salts 1 to 34). The 
1
H NMR 
spectra of compounds 36 to 39 possess a resonance at δ 8.00 characteristic of the 
acidic hydrogen atom of the 2 position (bonded to the carbon atom between the 
two nitrogen atoms), The resonances of the peaks of the 2'-methyl hydrogen 
atoms of compounds from 40 to 42 were similar to those of compounds 9 to 12 in 
the second chapter. But in benzimidazole, further hydrogen atoms have been 
exhibited as a result of the phenylene ring attached in positions 4 and 5 of the 
imidazole ring in these compounds, and the four hydrogen atoms of this ring have 
shown resonances from δ 7.9 and 7.0 ppm. The 13C NMR spectra have been 
collected for compounds 38 and 42, and they display similar resonances.  
For example, C2 of 38 displayed a resonance at  147 and  150 for 42, C5 
displayed a resonance at  110 for 38 and 109 for 42, C8 displayed a resonance at 
 121 for 38 and 119 for 42, C9 and C4 displayed resonances at  132 for 38 and 
134 for 42. Similar resonances are displayed for the other carbon atoms of 38 and 
42, Ca gave 127, Cb with Cf and Cc with Ce, have shown two multiple peaks at 
the resonances of δ 144 and 136-138 ppm respectively and C6 gave 124 ppm. The 
difference between the compounds is the presence of methyl group in 42 in the 2` 
position and the carbon atom of this group has shown single peak with resonance 
at 13 ppm.  
The chemical structures of 42 were confirmed through the data that has been 
collected by two dimensional NMR spectrum (HSQC and HMBC). For 42 in the 
HSQC spectrum H−2` correlates with C−2`, H−5 correlates with C−5, H−6 and 
H−7 correlates with C−6 and C−7, and H−8 correlates with C−8 (Fig. 54). In the 
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HMBC spectrum H−2` correlates with C−2`and C−2, H−5 correlates with C−5, 
C−4, C−6 and C−7, H−6 and H−7 correlates with C−4, C−5, C−6, C−7, C−8 and 
C−9, H−8 correlates with C−6, C−7, C−8 and C−9 (Fig. 55). Salt 44 has shown 
instability, slowly decomposing in methanol over months as shown in Figure 56. 
The IR spectral data of 36, 37, 38, 39, 40, 41, 42 and 44 were as expected. The 
elemental composition of 42 was calculated to be C = 55.53 %, H = 2.51 % and N 
= 14.94 %, and found to be C = 55.55 %, H = 2.62 % and N = 15.03 %. 
71 
 
 
Figure 54: The HSQC spectrum of 1-(2,3,5,6- tetrafluoropyridyl)-2-methylbenzimidazole 42.
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Figure 55: The HMBC spectrum of 1-(2,3,5,6- tetrafluoropyridyl)-2-methylbenzimidazole 42. 
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Figure 56: Decomposing of 1-(2,3,5,6-tetrafluoropyridyl)-3-benzyl-benzimidazolium bromide 44 over months from yellow to blue.
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All the compounds were recrystallized from methanol by slow evaporation, but 
crystals suitable for single-crystal X-ray diffraction were obtained only for 42, 
which crystallized in space group Pca21 in the orthorhombic crystal system with 
two independent molecules in the asymmetric unit (Crystallographic data for 42 
has been shown in table 11, chapter 5). π-π stacking is evident shown in the 
crystal structure (Fig.58). The centroid-centroid distances are Dcent = 3.623 and 
3.960 Å, the angle ϕ = 5.96˚, and the stack shift s = 0.00 Å (Fig.59).  
There are two values of slip angle as a result of rotated layers, θ = 49.29˚ is the 
angle between the direction of the stack and the perpendiculars to the 
tetrafluoropyridyl ring, whereas, θ = 83.47˚ is the angle between the direction of 
the stack and the perpendiculars to 2-methylbenzimidazole ring in this compound. 
Bond lengths and selected angles have been given in the table 8. The bonds 
lengths and angles of 42A were very similar to those of 42B.  
The bonds lengths and angles of 42A were very similar to those of 42B. The range 
of bond lengths and experimental errors are 1.302(3) −1.497(3) Å in compound 
42A and 1.306(3) −1.486(3) Å in 42B. The range of angles are from 106.05(19)˚ 
of C1A-N2A-C3  to 132.6(19)˚ of C5 -C4A-C3A in 42A and from 105.45(18)˚ 
of C1B-N2B-C3D to 132.3(2)˚ C5B-C4B-N1B in 42B. Some torsion angles of 
42A are similar to those of 42B, such as the torsion angle of C9-N1-C4-C5, 
1.5(4)˚ in 42A and 1.4(4)˚ in 42B. Other torsion angles are considerably different. 
For example, C1A-N1A-C9A-C13A of 42A is 54.2(3)˚, which differs 
significantly from C1B-N1B-C9B-C13B 128.2(2)˚ of 42B by ca.74˚. 
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Figure 57: The crystal structure of 1-(2,3,5,6- tetrafluoropyridyl)-2-
methylbenzimidazole 42. 
 
Comp. 42A 
Data of 
42A 
Comp. 42B 
Data of 
42B 
F10A C10A 1.336(3) F10B C10B 1.337(3) 
F11A C11A 1.335(3) F11B C11B 1.335(3) 
F12A C12A 1.341(3) F12B C12B 1.340(3) 
F13A C13A 1.334(3) F13B C13B 1.337(3) 
N1A C9A 1.400(3) N1B C4B 1.399(3) 
N1A C1A 1.403(3) N1B C1B 1.408(3) 
N1A C4A 1.403(3) N1B C9B 1.414(3) 
N2A C1A 1.302(3) N2B C1B 1.307(3) 
N2A C3A 1.392(3) N2B C3B 1.401(3) 
N3A C11A 1.304(3) N3B C11B 1.306(3) 
N3A C12A 1.313(3) N3B C12B 1.313(3) 
C1A C2A 1.497(3) C1B C2B 1.486(3) 
C3A C8A 1.399(4) C3B C8B 1.393(3) 
C3A C4A 1.403(3) C3B C4B 1.395(3) 
C4A C5A 1.393(3) C4B C5B 1.395(3) 
C5A C6A 1.388(3) C5B C6B 1.392(3) 
C6A C7A 1.402(4) C6B C7B 1.393(4) 
C7A C8A 1.386(4) C9B C10B 1.381(3) 
C9A C13A 1.392(3) C9B C13B 1.388(3) 
C9A C10A 1.394(3) C7B C8B 1.389(4) 
C10A C11A 1.381(3) C10B C11B 1.389(3) 
C12A C13A 1.378(3) C12B C13B 1.378(3) 
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C9A N1A C1A 127.05(19) C1B N1B C9B 126.75(19) 
C9A N1A C4A 126.54(19) C4B N1B C9B 126.64(19) 
C1A N1A C4A 106.37(18) C4B N1B C1B 106.61(18) 
C1A N2A C3A 106.05(19) C1B N2B C3B 105.45(18) 
C11A N3A C12A 117.1(2) C11B N3B C12B 117.2(2) 
N2A C1A N1A 112.33(19) N2B C1B N1B 112.16(19) 
N2A C1A C2A 124.8(2) N2B C1B C2B 124.7(2) 
N1A C1A C2A 122.9(2) N1B C1B C2B 123.1(2) 
N2A C3A C8A 129.4(2) C8B C3B C4B 120.0(2) 
N2A C3A C4A 110.6(2) C8B C3B N2B 128.9(2) 
C8A C3A C4A 120.0(2) C4B C3B N2B 111.1(2) 
C5A C4A C3A 122.8(2) C5B C4B C3B 123.0(2) 
C5A C4A N1A 132.6(2) C5B C4B N1B 132.3(2) 
C3A C4A N1A 104.63(19) C3B C4B N1B 104.70(19) 
C6A C5A C4A 116.4(2) C6B C5B C4B 115.8(2) 
C5A C6A C7A 121.7(2) C5B C6B C7B 122.0(2) 
C8A C7A C6A 121.6(2) C10B C9B C13B 117.2(2) 
C7A C8A C3A 117.5(2) C10B C9B N1B 121.7(2) 
C13A C9A C10A 116.4(2) C13B C9B N1B 121.2(2) 
C13A C9A N1A 121.96(19) C8B C7B C6B 121.3(2) 
C10A C9A N1A 121.6(2) C7B C8B C3B 117.9(2) 
F10A C10A C11A 120.7(2) F10B C10B C9B 121.3(2) 
F10A C10A C9A 120.1(2) F10B C10B C11B 119.9(2) 
C11A C10A C9A 119.2(2) C9B C10B C11B 118.8(2) 
N3A C11A F11A 117.2(2) N3B C11B F11B 117.2(2) 
N3A C11A C10A 124.0(2) N3B C11B C10B 123.9(2) 
F11A C11A C10A 118.9(2) F11B C11B C10B 118.9(2) 
N3A C12A F12A 116.8(2) N3B C12B F12B 117.2(2) 
N3A C12A C13A 124.5(2) N3B C12B C13B 124.2(2) 
F12A C12A C13A 118.7(2) F12B C12B C13B 118.7(2) 
F13A C13A C12A 120.6(2) F13B C13B C12B 120.3(2) 
F13A C13A C9A 120.7(2) F13B C13B C9B 121.0(2) 
C12A C13A C9A 118.7(2) C12B C13B C9B 118.7(2) 
    
    
C3A N2A C1A N1A 0.4(2) C3B N2B C1B N1B -0.7(2) 
C3A N2A C1A C2A 178.9(2) C3B N2B C1B C2B -178.3(2) 
C9A N1A C1A N2A 178.68(19) C9B N1B C1B N2B 178.96(19) 
C4A N1A C1A N2A 0.7(2) C4B N1B C1B N2B -0.3(2) 
C9A N1A C1A C2A 0.2(3) C9B N1B C1B C2B -3.4(3) 
C4A N1A C1A C2A 177.81(19) C4B N1B C1B C2B 177.3(2) 
C1A N2A C3A C8A 179.7(2) C1B N2B C3B C8B -179.2(2) 
C1A N2A C3A C4A -1.3(2) C1B N2B C3B C4B 1.5(2) 
N2A C3A C4A C5A -179.09(19) N2B C3B C4B C5B 178.8(2) 
C8A C3A C4A C5A 0.0(3) C8B C3B C4B C5B -0.5(3) 
N2A C3A C4A N1A 1.7(2) N2B C3B C4B N1B -1.7(2) 
C8A C3A C4A N1A -179.18(19) C8B C3B C4B N1B 179.00(18) 
C9A N1A C4A C5A 1.5(4) C9B N1B C4B C5B 1.4(4) 
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C1A N1A C4A C5A 179.5(2) C1B N1B C4B C5B -179.4(2) 
C9A N1A C4A C3A -179.44(19) C9B N1B C4B C3B -178.07(19) 
C1A N1A C4A C3A -1.4(2) C1B N1B C4B C3B 1.2(2) 
C3A C4A C5A C6A 0.8(3) C3B C4B C5B C6B -0.9(3) 
N1A C4A C5A C6A 179.7(2) N1B C4B C5B C6B 179.8(2) 
C4A C5A C6A C7A -0.7(3) C4B C5B C6B C7B 1.0(3) 
C5A C6A C7A C8A -0.1(3) C5B C6B C7B C8B 0.1(4) 
C6A C7A C8A C3A 0.9(3) C6B C7B C8B C3B -1.5(3) 
N2A C3A C8A C7A 178.0(2) N2B C3B C8B C7B -177.5(2) 
C4A C3A C8A C7A -0.8(3) C4B C3B C8B C7B 1.7(3) 
C1A N1A C9A C13A 54.2(3) C1B N1B C9B C13B 128.2(2) 
C4A N1A C9A C13A -128.2(2) C4B N1B C9B C13B -52.7(3) 
C1A N1A C9A C10A -126.0(2) C1B N1B C9B C10B -52.1(3) 
C4A N1A C9A C10A 51.6(3) C4B N1B C9B C10B 127.0(2) 
C13A C9A C10A F10A 179.60(18) C13B C9B C10B F10B 177.07(19) 
N1A C9A C10A F10A -0.2(3) N1B C9B C10B F10B -2.6(3) 
C13A C9A C10A C11A -1.4(3) C13B C9B C10B C11B -2.8(3) 
N1A C9A C10A C11A 178.77(19) N1B C9B C10B C11B 177.5(2) 
C12A N3A C11A F11A -178.79(18) C12B N3B C11B F11B -179.5(2) 
C12A N3A C11A C10A 2.4(3) C12B N3B C11B C10B 0.3(3) 
F10A C10A C11A N3A 177.56(19) F10B C10B C11B N3B -177.1(2) 
C9A C10A C11A N3A -1.5(3) C9B C10B C11B N3B 2.8(4) 
F10A C10A C11A F11A -1.2(3) F10B C10B C11B F11B 2.6(3) 
C9A C10A C11A F11A 179.76(18) C9B C10B C11B F11B -177.5(2) 
C11A N3A C12A F12A 179.69(18) C11B N3B C12B F12B 177.8(2) 
C11A N3A C12A C13A -0.5(3) C11B N3B C12B C13B -3.2(3) 
N3A C12A C13A F13A 177.34(19) N3B C12B C13B F13B -176.4(2) 
F12A C12A C13A F13A -2.9(3) F12B C12B C13B F13B 2.6(3) 
N3A C12A C13A C9A -2.3(3) N3B C12B C13B C9B 3.0(4) 
F12A C12A C13A C9A 177.51(18) F12B C12B C13B C9B -177.98(19) 
C10A C9A C13A F13A -176.55(18) C10B C9B C13B F13B 179.59(19) 
N1A C9A C13A F13A 3.3(3) N1B C9B C13B F13B -0.7(3) 
C10A C9A C13A C12A 3.1(3) C10B C9B C13B C12B 0.2(3) 
N1A C9A C13A C12A -177.1(2) N1B C9B C13B C12B 179.9(2) 
 
Table 8: Selected bond lengths (Å) and bond and torsion angles (˚) for 
compounds 42A and 42B.  
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Figure 58: The orthorhombic crystal system of 1-(2,3,5,6-tetrafluoropyridyl)-2-
methylbenzimidazole 42. 
 
Figure 59: The crystal structure of 1-(2,3,5,6-tetrafluoropyridyl)-2-
methylbenzimidazole 42. 
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Figure 60: The crystal packing of 1-(2,3,5,6-tetrafluoropyridyl)-2-
methylbenzimidazole 42 viewed along the C-C5F4N bond.
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4.Chapter Four: 
 
 
4.1. Conclusion:  
 
In this project a number of new compounds containing both aryl and 
polyfluoroaryl groups have been synthesized in variable yields using nucleophilic 
aromatic substitution and subsequent functionalization. All the reactions have 
been done at ambient temperature except the reactions of the compounds 8, 12, 
16, 17 and 18 have been heated from 55˚ C to 142˚ C. The compounds were 
characterized by MS (micro-TOF), IR spectroscopy, micro-elemental analysis and 
NMR spectroscopy. Two dimensional spectra, such as HSQC and HMBC have 
been determined for compounds 12, 18, and 42, which confirmed their 
characterization. The imidazolium salts, such as 1-(2,3,5,6-tetrafluoropyridil)-3-
benzyl-4-methylimidazolium bromide (34), were recrystallized from methanol. 
The benzimidazolium salts, such as 1-(2,3,5,6-tetrafluoropyridyl)-3-benzyl-
benzimidazolium bromide (44) were not stable in methanol, decomposing slowly 
over months. Attempts were made to grow crystals suitable for single-crystal X-
ray diffraction.  Single crystals were obtained only for 1-(4-bromo-2,3,5,6-
tetrafluorbenzyl)-3-benzyl-4-methylimidazolium bromide (26), 1-(2,3,5,6-
tetrafluoropyridil)-3-benzyl-4-methylimidazolium bromide (34) and 1-(2,3,5,6-
tetrafluoropyridyl)-2-methylbenzimidazole (42). 
 All three structures possess π-π stacking between the polyfluoroaryl group of one 
synthon and the aryl group of another. Attempts were made to synthesize 1-
(2,3,5,6-tetrafluoropyridyl)pyrazole (25) and 1-(2,3,5,6-
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tetrafluoropyridyl)indazole (43), which were envisaged to biological activity. In 
the future, more studying can be done to study the biological and pharmaceutical 
properties of these compounds with more interpretation of their role in crystal 
engineering. This project has established that a range of synthons for crystal 
engineering based on heterocycles beareing aryl and polyfluoroaryl groups may 
be readily prepared by the aromatic nucleophilic substitution reaction between the 
heterocycle and a polyfluoroarene.  The π-π stacking exhibited by 26, 34 and 42, 
as well for similar compounds reported previously, appears to be a general and 
robust interaction.     
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5.Chapter Five: 
 
 
5.1. General Synthesis: 
 
 
The starting materials of all the compounds from 1 to 25 and from 35 to 43 were 
dissolved in THF, DMSO or both, and then stirred for different periods of time at 
temperatures between RT and 142˚C, whereas the starting materials of the salts 
from 26 to 34 and salt 44 were dissolved in CH2Cl2 and stirred for a few days at 
room temperature. The solvents of these compounds and salts were removed by 
rotary evaporation. Their products were extracted into dichloromethane, which 
was then evaporated under reduced pressure to yield the products. The 
recrystallization of these products from methanol and of compounds 5 and 6 from 
diethyl ether led to an increase in purity, except for salts 26, 34, 44 and compound 
42. Crystals of 26, 34 and 42 were grown from methanol and were analysed by 
XRD. In contrast, using methanol with salt 44 led to decomposition. The reactions 
of the expected compounds from 2 to 6 have not yet been completed. The slow 
rates of these reactions were shown by the NMR spectrum that was recorded over 
a period of months and the mass of these expected compounds was confirmed by 
MS analysis.  
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5.2. Imidazole: 
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Figure 61: The general reaction of polyfluoroaryl and imidazole with their 
derivatives and examples of imidazolium salts (with the labels that have been used 
to represent the NMR data) (R = Br, I, F. R
1
, R
2
 = H, CH3. R1, R2, R3 = H, F). 
. 
 
5.2.1. 1-(2,3,6-Trifluorobenzonitrile)imidazole (1): 
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0.103 g of imidazole was dissolved in 50 ml of THF, which then was added to 
0.151 g of 2,3,4,5- tetrafluorobenzonitrile, and then the solution was left at RT for 
a day. C10H4F3N3: 223.1569 g.mol
−1
. (93.28 % yield). MS: Calc. 224.0436. Found. 
224.0490 m/z [(M + H)+]. In CDCl3 (400 MHz), 
1H NMR: δ = 7.85 (m, 1H, H−2), 
7.43 (m, 1H, H−5) and 7.31 (q, J = 0.77 Hz, J` = 0.77 Hz, 2H, H−4 and H−e`) 
ppm. 
19F NMR: δ = −121.33 (t, J = 10.39 Hz, 12.52 Hz, 1F, F−f`), −130.53 (m, 
1F, F−c`) and −137.92 (d, J = 11.34, 9.17 Hz, 1F, F−b`) ppm. IR (KBr): 3157, 
3006, 2240, 1643, 1619, 1517, 1495, 1467, 1400, 1375, 1349, 1303, 1275, 1255, 
1233, 1175, 1111, 1087, 1062, 1048, 1029, 959, 916, 898, 876, 849, 827, 745, 
714, 653, 615, 590, 574, 485, 468 and 449 cm
-1
. 
 
5.2.2. The Expected Compound 1-(3,4,6-Trifluoropyridyl)imidazole (2): 
 
A solution of (0.086 g) of imidazole in THF was added to 0.165 g of 2,3,5,6-
tetrafluoropyridine, and then the mixture was left for several months at RT. 
C8H4F3N3: 199.0357 g.mol
−1
. MS: Calc. 200.0436. Found. 200.9464 m/z [(M + 
H)
+
]. NMR analysis has been recorded in CDCl3 with (400 MHz) and show a slow 
rate of interaction (Fig. 38, chapter two). 
 
5.2.3. The Expected Compound 1-(2,3-Difluorobenzonitrile)imidazole (3): 
 
 0.086 g of imidazole was dissolved in THF, and then added to 0.203 g of 2,3,4-
trifluorobenzonitrile, then this mixture was left at RT for several months. 
C10H5F2N3: 205.1664 g.mol
−1
. MS: Calc. 206.0530. Found. 206.0483 m/z [(M + 
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H)
+
], NMR analysis has been recorded in CDCl3 with (400 MHz) and show a slow 
rate of interaction (Fig. 39, chapter two). 
 
5.2.4. The Expected Compound 1-(3,4,6-Trifluorobenzonitrile)imidazole (4): 
 
0.039 g of imidazole was dissolved in THF, and then added to 0.117 g of 2,3,5,6-
tetrafluorobenzonitrile, then this mixture was left at RT for several months. 
C10H4F3N3: 223.1569 g.mol
−1
. MS: Calc. 224.0436. Found: 224.9958 m/z [(M + 
H)
+
]. NMR analysis has been recorded in CDCl3 with (400 MHz) and show a slow 
rate of interaction (Fig. 40, chapter two). 
 
5.2.5. The Expected Compound 1-(4,6-Difluoropyridyl)imidazole (5): 
 
A solution of 0.086 g of imidazole and 0.180 g of 2, 3, 5-trifluoropyridine in THF 
was left for several months at RT. C8H5F2N3: 181.0452 g.mol
−1
. MS: Calc. 
182.0530. Found. 182.0914 m/z [(M + H)
+
]. NMR analysis has been recorded in 
CDCl3 with (400 MHz) and show a slow rate of interaction (Fig. 41, chapter two). 
 
5.2.6. The Expected Compound 1-(3,6-Difluorobenzonitrile)imidazole (6): 
 
0.050 g of imidazole was dissolved in 50 ml of THF then added to 0.115 g of 
2,4,5-trifluorobenzonitrile, Then it was left for several months at RT. C10H5F2N3: 
205.1664 g.mol
−1
. MS: Calc. 206.0530. Found. 206.0385 m/z [(M + H)
+
]. NMR 
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analysis has been recorded in CDCl3 with (400 MHz) and show a slow rate of 
interaction (Fig. 42, chapter two). 
 5.2.7. 1-(Heptafluorotolyl)imidazole (7): 
 
0.179 g of imidazole was dissolved in 50 ml of THF then added to 0.595 g of 
1,2,3,4,5-pentafluoro-6-(trifluoromethyl)benzene, Then it was left for a day at RT. 
C10H3F7N2: 284.1359 g.mol
−1
. (36.87% yield). MS: Calc. 285.0263. Found. 
285.3625 m/z [(M + H)
+
]. In CDCl3 (400 MHz),
 1H NMR: δ = 7.85 (m, 1H, H-2), 
7.31 (m, 1H, H−5), 7.29 (m, 1H, H−4) ppm. 19F NMR: δ = −56.19 (t, J = 21.74 
Hz, 3F, F−d`), −137.94 (m, 2F, F−c` and F−e`) and −146.19 (m, 2F, F−b` and 
F−f`) ppm. 
 
5.2.8. 1-(5-Bromo-3,4,6-trifluorobenzotrifluoride)imidazole (8a) and 1-(6-
Bromo-3,4,5-trifluorobenzotrifluoride)imidazole (8b): 
 
A solution of imidazole (0.157 g) in THF was added to 0.508 g of 4-bromo-
2,3,5,6-tetrafluorobenzotrifluoride, then this was heated at 80˚C for 8 days. 
C10H3F6N2Br: 345.0415 g.mol
−1
. (60.83 % yield) MS: Calc. 346.9558. Found. 
346.9389 m/z [(M + H)
+
]. In CDCl3 (400 MHz), 
1H NMR: δ = 7.13 (d, J = 0.99 
Hz, 2H, H−2, in a and b), 7.01 (d, J = 0.66 Hz, 4H, H−4 & H−5, in a and b) ppm. 
19F NMR: δ = −55.47 (m, 3F, F−b or F−e, in a or b), −56.18 (d, J = 13.56, J = 
12.44 Hz, 3F, F−b or F−e, in a or b), −130.70 (m, 1F, F−f` in a or b), −130.91 (m, 
2F, F−c` & F−d` in a or b), −144.59 (m, 1F, F−f` in a or b), −146.98 (m, 2F, F−c` 
& F−d` in a or b) ppm. 
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5.2.9. 1-(2,3,5,6-Tetrafluorobenzonitrile)-2-methylimidazole (9): 
 
0.162 g of 2-methylimidazole was dissolved in 50 ml of THF then added to 0.375 
g of pentafluorobenzonitrile, then left for three days at room temperature. 
C11H5F4N3: 255.1742 g.mol
−1
. (72.65 % yield). MS: Calc. 256.0498. Found. 
256.0382 m/z[(M + H)
+
]. In CDCl3 (400 MHz), 
1H NMR: δ = 7.18 (d, J = 1.58 Hz, 
1H, H−5), 6.98 (q, J` = 1.54 Hz, J = 1.21 Hz, 1H, H−4), 2.36 (t, J = 1.09 Hz, 3H, 
H−2`) ppm.19F NMR: δ = −192.94 (m, 2F, F−c` and F−e`) and −142.15 (m, 2F, 
F−b` and F−f`) ppm. 
 
5.2.10. 1-(2,3,5,6-Tetrafluoropyridyl)-2-methylimidazole (10): 
 
0.270 g of 2-methylimidazole was dissolved in 50 ml of THF then added to 0.540 
g of pentafluoropyridine, then the solution was left over night at RT. C9H5F4N3: 
231.1522 g.mol
−1
. (95.24 % yield). MS: Calc. 232.0498. Found. 232.0513 m/z 
[(M + H)
+
]. In CDCl3 (400 MHz), 
1H NMR: δ = 7.21 (d, J = 1.65 Hz, 1H, H−5), 
7.05 (q, J = 1.32 Hz, J`= 1.32 Hz, 1H, H−4), 2.43 (t, J = 1.21 Hz, 3H, H−2`) ppm. 
19F NMR: δ = −86.10 (m, 2F, F−c` and F−e`) and -146.10 (m, 2F, F−b` and F−f`) 
ppm. 
 
5.2.11. 1-(Heptafluorotolyl)-2-methylimidazole (11): 
 
0.188 g of 2-methylimidazole was dissolved in THF, and then added to 0.540 g of 
octafluorotoluene, and then this mixture was left at RT for 2 days. C11H5F7N2: 
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298.1627 g.mol
−1
. (76.44 % yield). MS: Calc. 299.0419. Found. 299.0258 m/z 
[(M + H)
+
]. In CDCl3 (400 MHz), 
1H NMR: δ = 7.11 (d, J = 0.56 Hz, 1H, H−5), 
6.95 (m, 1H, H−4) and 5.27 (t, J = 0.35 Hz, 0.43 Hz, 3H, H−2`) ppm. 19F NMR: δ 
= −56.49 (t, J = 21.92 Hz, 3F, F−d`), −138.87 (m, 2F, F−c` and F−e`) and −143.95 
(m, 2F, F−b` and F−f`) ppm. 
 
5.2.12. 1-(4-Bromo-2,3,5,6-tetrafluorobenzyl)-2-methylimidazole (12): 
 
1.65 g of 2-methylimidazole was dissolved in 10 ml of THF and 20 ml of DMSO 
then added to 4.95 g of bromopentafluorobenzene, then the solution was heated at 
80˚C for 8 days. C10H5F4N2Br: 309.0605 g.mol
−1
. (30 % yield). MS: Calc. 
308.9650. Found. 308.9621 m/z [(M + H)
+
]. In CDCl3 (400 MHz), 
1H NMR: δ = 
7.13 (d, J = 1.54 Hz, 1H, H−5), 6.95 (q, J = 0.66 Hz, J`= 0.88 Hz, 1H, H−4) and 
2.62 (s, J = 6.99 Hz, 3H, H−2`) ppm. 19F NMR: δ = −130.70 (m, 2F, F−c` and 
F−e`) and −144.58 (m, 2F, F−b` and F−f`) ppm. 13C NMR: δ = 145.77 (s, J = 
23.85 Hz, 1C, C−2), 145.27 (dm, J = 249.53 Hz, 2C, C−b & C−f), 142.82 (dm, J = 
254.27 Hz, C−c & C−e), 129.10 (s, J = 16.28 Hz, 1C, C−5), 120.64 (s, J = 29.24 
Hz, 1C, C−4), 116.70 (m, 1C, C−a), 101.38 (t, J = 22.41 Hz, 1C, C−d) and 12.81 
(s, J = 22.61 Hz, 1C, C−2`) ppm. The HSQC spectrum shows that H−2` correlates 
with C−2`, H−4 correlates with C−4, H−5 correlates with C−5 (Fig. 34, chapter 
two). The HMBC spectrum shows that H−2` correlates with C−2`and C−2 and 
H−4 correlates with C−2, C−4, C−5 and H−5 correlates with C−2, C−4 and C−5 
(Fig. 35, chapter two). IR (KBr): 3437, 1587, 1493, 1395, 1319, 1300, 1209, 
1165, 1132, 1082, 1021, 973, 850, 792, 733, 686, 663, 630, 614, 470 and 441 cm
1
. 
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5.2.13. 1-(2,3,5,6-Tetrafluorobenzonitrile)-4-methylimidazole (13): 
 
0.157 g of 4-methylimidazole was dissolved in 50 ml of THF then added to 0.370 
g of pentafluorobenzonitrile, then left for 24 hrs at room temperature. C11H5F4N3: 
255.1742 g.mol
−1
. (100 % yield). MS: Calc. 256.0498. Found. 256.0400 m/z [(M 
+ H)
+
]. In CDCl3 (400 MHz),
 1H NMR: δ = 7.77 (m, 1H, H−2), 6.99 (m, 1H, 
H−5), 2.19 (m, 3H, H−4`) ppm. 19F NMR: δ = −130.95 (m, 2F, F−c` and F−e`) 
and −145.36 (m, 2F, F−b` and F−f`) ppm.  
 
5.2.14. 1-(2,3,5,6-Tetrafluoropyridyl)-4-methylimidazole (14): 
 
0.307 g of 4-methylimidazole was dissolved in THF then added to 0.576 g of 
pentafluoropyridine, then the solution was left a week at RT. C9H5F4N3: 231.1522 
g.mol
−1
. (102 % yield) MS: Calc. 232.0498. Found. 232.0506 m/z [(M + H)
+
]. In 
CDCl3 (400 MHz), 
1H NMR: δ = 7.96 (d, J = 0.77 Hz, J` = 0.88 Hz, 1H, H−2), 
7.14 (m, 1H, H−5) and 2.36 (d, 0.54 Hz, 3H, H−4`) ppm. 19F NMR: δ = −87.06 
(m, 2F, F−c` and F−e`) and −149.30 (m, 2F, F−b` and F−f`) ppm. IR (KBr): 3436, 
1631, 1527, 1481, 1392, 1264, 1150, 1084, 971, 744, 657, 625, and 483 cm
-1
. 
 
5.2.15. 1-(Heptafluorotolyl)-4-methylimidazole (15): 
 
To 0.576 g of octafluorotoluene, 0.200 g of 4-methylimidazole in 50 ml of THF 
has been added, and then it was left at RT for 48 hrs. C11H5F7N2: 298.1627 
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g.mol
−1
. (75.67 % yield). MS: Calc. 299.0419. found. 299.0316 m/z [(M + H)
+
]. In 
CDCl3 and DMSO (400 MHz), 
1H NMR: δ = 7.75 (q, J = 0.82 Hz, J`= 1.88 Hz, 
1H, H−2), 6.99 (m, 1H, H−5) and 2.32 (d, J = 0.55 Hz, 3H, H−4`) ppm. 19F NMR: 
δ = −56.21 (t, J = 21.72 Hz, 3F, F−d`), −138.34 (m, 2F, F−c` and F−e`) and 
−146.48 (m, 2F, F−b` and F−f`) ppm. 
 
5.2.16. 1-(4-Bromo-2,3,5,6-tetrafluorobenzyl)-4-methylimidazole (16): 
 
1.65 g of 4-methylimidazole was dissolved in 10 ml of THF and 20 ml of DMSO 
then added to 4.95 g of bromopentafluorobenzene, and then the solution was 
heated at 80˚C for 4 days. C10H5F4N2Br: 309.0605 g.mol
−1
. (42 % yield). MS: 
Calc. 308,9650. Found. 308.9555 m/z [(M + H)
+
]. In CDCl3   (400 MHz), 
1
H 
NMR: δ = 7.72 (m, 1H, H-2), 6.94 (m, 1H, H-5) and 2.63 (s, J = 3.16 Hz, 3H, H-
4`) ppm. 
19F NMR: δ = −130.836 (m, 2F, F-c` and F-e`) and −146.937 (m, 2F, F-
b` and F-f`) ppm. IR (KBr): 3434, 3118, 2930, 1638, 1519, 1494, 1448, 1376, 
1303, 1289, 1253, 1233, 1212, 1150, 1031, 1004, 974, 831, 792, 742, 661, 633, 
608 and 423 cm
-1
. 
 
5.2.17. 1-(2,3,5,6-Tetrafluorobenzyl)-4-methylimidazole (17): 
 
 1.75 g of pentafluorobenzene was added to a solution of 4-methylimidazole 
(0.867g) and KOH (0.638 g) in 5 ml of DMSO, and then the mixture was heated 
at 55˚C for 3 hrs. C10H6F4N2: 230.1644 g.mol
−1
. (29.46 % yield). MS: Calc. 
231.0545. Found. 231.0486 m/z [(M + H)
+
]. In CDCl3 (400 MHz),  
1H NMR: δ = 
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7.66 (m, 1H, H−2, in a or b), 7.49 (d, J = 0.39 Hz, 1H, H−2, in a or b ), 7.26 (m, 
1H, H−5, in a or b), 7.14 (m, 1H, H−5, in a or b), 6.97 (t, J = 1.00 Hz, 1H, H−d` 
or H−f`, in a or b), 6.92 (m, 1H, H−d` or H−f`, in a or b), 2.60 (s, J = 6.36 Hz, 
3H, H−4`, in a or b), 2.30 (d, J = 0.44 Hz, 3H, H−4`, in a or b) ppm. 19F NMR: δ 
= −131.08 (m, 1F, F−e`, in b), −136.75 (m, 1F, F−d`, in b), −136.93 (m, 2F, F−c` 
& F−e`, in a), −146.28 (m, 1F, F−c`, in b), −147.05 (m, 1F, F−b`, in b) and 
−148.60 (m, 2F, F−b` & F−f`, in a) ppm. 
 
 5.2.18. 1-(4-Iodo-2,3,5,6-tetrafluorobenzyl)-4-methylimidazole (18): 
 
A solution of iodopentafluorobenzene (2.98 g) in 10 ml of THF was added to a 
solution of 4-methylimidazole (0.863 g) in10 ml of DMSO, and then the mixture 
was heated for 45 hrs at 80˚C. C10H5F4N2I: 356.061 g.mol
−1
. (92.50 % yield). MS: 
Calc. 356.9512. Found. 356.9573 m/z [(M + H)
+
]. In CDCl3 (400 MHz), 
1
H NMR: 
δ = 7.68 (m, 1H, H−2), 6.93 (m, 1H, H−5), 2.32 (d, J = 0.99 Hz, 3H, H−4`) ppm. 
19F NMR: δ = −114.53 (m, 2F, F−c` and F−e`) and −142.37 (q, J = 13.67 Hz, J` = 
8.65 Hz, 2F, F−b` and F−f`) ppm. 13C NMR: δ = 147.54 (dm, J = 244.03 Hz, 2C, 
C−b & C−f), 140.58 (dm, J = 254.88 Hz, 2C, C−c & C−e), 138.68 (s, J = 28.32 
Hz, 1C, C−2), 136.87 (s, J = 34.24 Hz, 1C, C−5), 117.22 (t, J = 13.90 Hz, 1C, 
C−a), 116.38 (s, J = 30.68 Hz, 1C, C−4), 73.57 (t, J = 28.62 Hz, 1C, C−d) and 
13.38 (s, J = 16.60 Hz, 1C, C−4`) ppm. The HSQC spectrum shows that H−4` 
correlates with C−4`, H− 2 correlates with C−2, H−5 correlates with C−5 (Fig. 36, 
chapter two). The HMBC spectrum shows that H−4` correlates with C−4`, C−4 
and C−2, H−2 correlates with C−2, C−4 and C−5, H−5 correlates with C−2, C−4 
and C−5 (Fig. 37, chapter two). IR (KBr): 6161, 1578, 1484, 1309, 1248, 1227, 
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1211, 1146, 1081, 1034, 1004, 967, 866, 821, 804, 775, 748, 649, 628, 611 and 
428 cm
-1
. 
 
5.2.19. 1-(2,3,5,6-Tetrafluorobenzonitrile)-2-phenylimidazole (19): 
 
0.372 g of 2-phenylimidazole was dissolved in 50 ml of THF then added to 0.506 
g of pentafluorobenzonitrile and then the solution was heated at 60
◦
C for 92 hrs. 
C16H7F4N3: 317.245 g.mol
−1
. (61.24 % yield). MS: Calc. 318.0654. Found. 
318.0641 m/z [(M + H)
+
]. In CDCl3 (400 MHz), 
1H NMR: δ = 7.91 (m, 1H, H-5), 
7.41 (m, 1H, H-4) and 7.24 (dd, J = 39.85 Hz, J`= 6.98 Hz, 5H, H-ph) ppm. 
19
F 
NMR: δ = −129.85 (m, 2F, F-c` and F-e`) and −141.97 (m, 2F, F-b` and F-f`) 
ppm. IR (KBr): 1505, 1462, 1417, 1106, 948, 769, 738, 705, and 684 cm
-1
.  
 
5.2.20. 1-(2,3,5,6-Tetrafluorobenzaldehyde)-2-phenylimidazole (20): 
 
0.322 g of 2-phenylimidazole and 0.433 g of pentafluorobenzaldehyde were 
dissolved in 60 ml of THF, then heated for 167 hrs, with the temperature 
increasing gradually from 85
◦
C to 142
◦
C.  C16H8F4 N2O: 320.2456 g.mol
−1
. (82.61 
% yield). MS: Calc. 321.0651. Found. 321.0721 m/z [(M + H)
+
]. In CDCl3 (400 
MHz),
 1H NMR: δ = 7.88 (m, 1H, H−d`), 7.41 (m, 1H, H−5), 7.17 (m, 1H, H−4) 
and 6.99 (d, J = 0.54 Hz, 5H, H-ph) ppm.
19F NMR; δ = −143.15 (m, 2F, F-c` and 
F-e`) and −144.18 (m, 2F, F-b` and F-f`) ppm. 
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5.2.21. 1-(2,3,5,6-Tetrafluoropyridyl)-2-phenylimidazole (21): 
 
0.445 g  of 2-phenylimidazole was dissolved in 50 ml of THF then added to 0.516 
g of penatfluoropyridine, and then it was left two days at RT. C14H7F4 N3: 293.223 
g.mol
−1
. (49.85 % yield). MS: Calc. 294.0654. Found. 294.0663 m/z [(M + H)
+
]. 
IR (KBr): 3053, 2992, 2828, 1570, 1505, 1462, 1416, 1397, 1302, 1185, 1137, 
1106, 948, 913, 769, 738, 684 and 444 cm
-1
. In CDCl3 and DMSO (400 MHz),
 1
H 
NMR: δ = 7.87 (m, 1H, H-5), 7.41 (m, 1H, H-4), 7.17 (s, J = 7.63 Hz, 5H, H−ph) 
ppm. 
19F NMR: δ = −86.27 (m, 2F, F-c` and F-e`) and −145.88 (m, 2F, F-b` and 
F-f`) ppm. 
5.3. Pyrazole: 
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Figure 62: The general reaction of polyfluoroaryl and pyrazole and their 
derivatives (with the labels that have been used to represent the NMR data, R
1
, R
2
 
= H, CH3). 
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5.3.1. 1-(2,3,5,6-Tetrafluorobenzonitrile)pyrazole (22): 
 
0.129 g of pyrazole was dissolved in THF then added to 0.370 g of 
pentafluorobenzonitrile, and then the solution was heated for 93 hrs, with increase 
the temperature gradually from 95
◦
C to 140
◦
C. C10H3F4N3: 241.1474 g.mol
−1
. 
(33.51 % yield). MS: Calc. 242.0341. Found. 242.1665 m/z [(M + H)
+
]. In CDCl3 
and DMSO (400 MHz), 
1H NMR: δ = 7.92 (m, 1H, H−5), 7.83 (m, 1H, H−3) and 
6.62 (m, 1H, H−4) ppm. 19F NMR; δ = −130.86 (m, 2F, F−c` and F−e`) and -
144.63 (m, 2F, F−b` and F−f`) ppm. Crystals were obtained by the slow 
evaporation of 1-(2,3,5,6−tetrafluorobenzonitrile)pyrazole in methanol, but the 
purity of these crystals was not enough to be analyzed by 
13
C NMR and XRD. 
 
 5.3.2. 1-(2,3,5,6-Tetrafluorobenzonitrile)-3,5-dimethylpyrazole (23): 
 
0.233 g of 3,5-dimethylpyrazole was dissolved in THF, then added to 0.473 g of 
pentafluorobenzonitrile, and then the solution was heated at 85
◦
C for 28 hrs. 
C12H7F4N3: 269.201 g.mol
−1
. (110 % yield). MS: Calc. 270.0654. Found. 
270.0639 m/z [(M + H)
+
]. In CDCl3 and DMSO (400 MHz), 
1H NMR: δ = 6.11 
(m, 1H, H−4), 2.32 (m, 3H, H−5`) and 2.23 (m, 3H, H−3`) ppm. 19F NMR; δ = 
−131.20 (m, 2F, F−c` and F−e`) and −141.95 (m, 2F, F−b` and F−f`) ppm. 
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 5.3.3. 1-(2,3,5,6-Tetrafluoropyridyl)-3,5-dimethylpyrazole (24): 
 
0.354 g of 3,5-dimethylpyrazole was dissolved in 50 ml of THF then added to 
0.570 g of pentafluoropyridine, then the solution was left for17 days at RT. 
C10H7F4N3: 245.179 g.mol
−1
. (62.80 % yield). MS: Calc. 246.0654. Found. 
246.0661 m/z [(M + H)
+
]. In CDCl3 (400 MHz), 
1H NMR: δ = 6.13 (s, J = 14.44 
Hz, 1H, H-4), 2.33 (s, J = 9.70 Hz, 3H, H−5`) and 2.27 (d, J = 0.90 Hz, 3H, H−3`) 
ppm. 
19F NMR: δ = −87.78 (m, 2F, F−c` and F−e`) and −146.03 (m, 2F, F−b` and 
F−f`) ppm. 
 
5.3.4. Attempt to synthesize 1-(2,3,5,6-Tetrafluoropyridyl)pyrazole (25): 
 
0.213 g of pyrazole was dissolved in THF then added to 0.563 g of 
pentafluoropyridine, and then the solution was left for a week at RT.  
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5.4. Imidazolium Salts: 
 
5.4.1. 1-(4-Bromo-2,3,5,6-tetrafluorobenzyl)-3-benzyl-4-methylimidazolium 
bromide (26): 
 
To 0.545 g of 1-(4-bromo-2,3,5,6-tetrafluorobenzyl)-4-methylimidazole (16) in 
CH2Cl2 was added 0.322 g of benzyl bromide has been added, and then this was 
left for two days at RT. C17H12F4N2Br2: 480.0968 g.mol
−1
. (93.26 % yield). MS: 
Calc. 400.0198 Found. 400.0157 m/z [(M − Br)+]. In CDCl3 and DMSO (400 
MHz), 
1H NMR: δ = 9.77 (s, J = 11.13 Hz, 1H, H−2), 7.97 (s, J = 12.37 Hz, 1H, 
H−5), 7.43 (m, 5H, H−3c,3d,3e,3f,3g), 5.61 (s, J = 10.31 Hz, 2H, H−3a) and 3.35 
(s, J = 9.25 Hz, 3H, H−4`) ppm. 19F NMR: δ = −132.25 (m, 2F, F−c` and F−e`) 
and −145.58 (m, 2F, F−b` and F−f`) ppm. IR (KBr): 3884, 3436, 3125, 3089, 
3025, 2969, 2940, 2825, 2405, 2307, 1904, 1877, 1809, 1770, 1622, 1613, 1568, 
1502, 1454, 1445, 1426, 1392, 1369, 1349, 1329, 1307, 1264, 1247, 1209, 1196, 
1165, 1148, 1075, 1047, 1024, 1002, 978, 877, 804, 769, 755, 726, 697, 677, 630, 
618, 571, 472, 426, 449, 429 and 419 cm
-1
. Crystallographic data for 26 has been 
shown in table 9. 
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Crystallographic data for 1-(1-bromo-2,3,5,6-tetrafluorophenyl)-4-
methylbenzimidazolium bromide   
__________________________________________________________________ 
Formula C17H12Br2F4N2 
Formula weight 480.11 
Crystal system monoclinic 
Space group I2/a 
a, Å 23.6805(3) 
b, Å 7.13235(7) 
c, Å 21.0790(2) 
Β, o 103.6307(11) 
V, Å
3
 3459.92(6) 
Z 8 
Dc (g cm
-3
) 1.843 
μ (mm-1) 6.353 
 range (o) 3.84 → 73.57 
Total reflections 17663 
Unique reflections (Rint) 3447(0.0515) 
Observed reflections [I > 2(I)] 3419 
Parameters 226 
Final R indices [I > 2(I)] R1 0.0372, wR2 = 0.0376 
R indices (all data) R1 = 0.1025, wR2 = 0.1029 
Weighting scheme w = 1/[σ2(Fo)
2 
+ {0.0607 (Fo
2
 + 2Fc
2
)/3}
2
 + 
11.1404 (Fo
2
 + 2Fc
2
)/3]] 
Max., min. Δρ (eÅ-3) 0.829, -1.327 
Goodness of fit on F
2
 1.550 
__________________________________________________________________ 
Table 9: Estimated standard deviations are given in parentheses. Data were 
collected at 100(2) K with graphite monochromated copper radiation (λ = 1.54184 
Å). 
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5.4.2. 1-(2,3,5,6-Tetrafluorobenzonitrile)-3-benzyl-4-methylimidazolium 
bromide (27): 
 
To 0.200 g of benzyl bromide was added 0.100 g of 1-(2,3,5,6-
tetrafluorobenzonitrile)-4-methylimidazole (13) in 50 ml of CH2Cl2, and then it 
was left at RT for 48 hrs. C18H12F4N3Br: 426.2105 g.mol
−1
. (113 % yield). MS: 
Calc. 346.0967. Found. 346.1087 m/z [(M − Br)+]. In CDCl3 (400 MHz), 
1
H 
NMR: δ = 7.35 (m, 7H, H−2,5,3c,3d,3e,3f,3g), 5.73 (s, J = 80.12 Hz, 2H, H−3a) 
and 2.12 (s, J = 5.40 Hz, 3H, H−4`) ppm. 19F NMR: δ = −127.82 (q, J = 6.77 Hz, 
J` = 4.44 Hz, 2F, F-c` and F-e`) and −141.98 (m, 2F, F−b` and F−f`) ppm. 
 
 5.4.3. 1-(2,3,6-Trifluorbenzonitrie)-3-benzyl-imidazolium bromide (28): 
 
0.065 g of 1-(2,3,6-trifluorobenzonitrile)imidazole (1) was dissolved in CH2Cl2 
0.0693 g of benzyl bromide was added and this mixture was left for two days at 
RT. C17H11F3N3Br: 394.1932 g.mol
−1
. (97.55 % yield). MS: Calc. 314.0905, 
Found. 314.0765 m/z [(M − Br)+]. In CDCl3 and DMSO (400 MHz),
 1H NMR: δ = 
9.93 (s, J = 12.40 Hz, 1H, H−2), 8.20 (m, 2H, H−4,5), 7.47 (m, 7H, 
H−f`,3c,3d,3e,3f,3g) and 5.62 (s, J` = 9.80 Hz, 2H, H−3a) ppm. 19F NMR: δ = 
−122.03 (d, J = 4.57Hz, J` = 9.20 Hz, 1F, F−f`), −133.35 (m, 1F, F−c`) and 
−137.76 (d, J = 10.30 Hz, 1F, F−b`) ppm. 
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5.4.4. 1-(2,3,5,6-Tetrafluoropyridyl)-3-benzyl-2-methylimidazolium bromide 
(29): 
0.267 g of benzyl bromide has been added to 0.314 g of 1-(2,3,5,6-
tetrafluoropyridyl)-2-methylimidazole (10) in CH2Cl2, which was left for 48 hrs. 
at RT. C16H12F4N3Br: 402.1885 g.mol
−1
. (92.07 % yield). MS: Calc. 322.0967 
Found. 322.0968 m/z [(M − Br)+]. In CDCl3 and DMSO (400 MHz), 
1H NMR: δ 
= 8.06 (m, 2H, H−4,5), 7.45 (m, 5H, H−3c,3d,3e,3f,3g), 5.56 (s, J = 9.10 Hz, 2H, 
H−3a ) and 3.35 (s, J = 10.47 Hz, 3H, H−2`) ppm. 19F NMR: δ = −88.11 (m, 2F, 
F−b` & F−f`) and −144.24 (m, 2F, F−c` & F−e`) ppm. 
 
 5.4.5. 1-(4-Bromo-2,3,5,6-tetrafluorobenzyl)-3-benzyl-2-methylimidazolium 
bromide (30): 
 
0.221 g of benzyl bromide was added to a solution of 0.353 g of 1-(4-bromo-
2,3,5,6-tetrafluorobenzene)-2-methylimidazole (12) in CH2Cl2, which was left for 
48 hr, at RT. C17H12F4 N2Br2: 480.0968 g.mol
−1
. (112 % yield). MS: Calc. 
400.0198. Found. 400.0144 m/z [(M − Br)+]. In CDCl3 and DMSO (400 MHz), 
1
H 
NMR: δ = 8.07 (s, J = 2.53 Hz, 2H, H−4,5), 7.45 (m, 5H, H−3c,3d,3e,3f,3g), 5.58 
(s, J = 8.40 Hz, 2H, H−3a ), 3.44 (s, J = 42.82 Hz, 3H, H−2`) ppm. 19F NMR: δ = 
−132.39 (m, 2F, F−c` & F−e`) and −145.25 (q, J = 16.00 Hz, J` = 8.00 Hz, 2F, 
F−b` & F−f`) ppm. IR (KBr): 3446, 3185, 3166, 3120, 3070, 3033, 2951, 1697, 
1640, 1581, 1534, 1511, 1496, 1428, 1395, 1375, 1334, 1319, 1300, 1261, 1244, 
1227, 1209, 1197, 1165, 1147, 1132, 1098, 1082, 1041, 1031, 1021, 975, 917, 
850, 838, 793, 760, 748, 734, 723, 702, 695, 688, 650, 621, 613, 547, 472, 451, 
442 and 413 cm
-1
. 
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5.4.6. 1-(Heptafluorotolyl)-3-benzylimidazolium bromide (31): 
 
A solution of 0.135 g of 1-(heptafluorotolyl)imidazole (7) and 0.152 g of benzyl 
bromide in CH2Cl2 was left for two days at RT. C17H10F7N2Br: 455.1722 g.mol
−1
. 
(98.84 % yield). MS: Calc. 375.0732, Found. 375.0558 m/z [(M − Br)+]. In CDCl3 
and DMSO (400 MHz), 
1H NMR: δ = 10.07 (s, J = 11.14 Hz, 1H, H-2), 8.20 (m, 
1H, H−5), 7.53 (m, 1H, H−4), 7.38 (m, 5H, H−3c,3d,3e,3f,3g), 5.67 (s, J = 7.75 
Hz, 2H, H−3a ) ppm. 19F NMR: δ = −55.93 (t, J = 21.75 Hz, 3F, F−d`), −139.49 
(m, 2F, F−c` and F−e` ) and −143.82 (m, 2F, F−b` and F−f`) ppm. 
 
5.4.7. 1-(Heptafluorotolyl)-3-benzyl-4-methylimidazolium bromide (32): 
To a solution of (0.516 g) 1-(heptafluorotolyl)-4-methylimidazole (15) in CH2Cl2, 
0.307 g of benzyl bromide was added, and then this mixture was left for two days 
at RT. C18H12F7N2Br: 469.199 g.mol
−1
. (97.40 % yield). MS: Calc. 389.0889. 
Found. 389.0722 m/z [(M − Br)+]. In CDCl3 and DMSO (400 MHz), 
1H NMR; δ 
= 11.27 (s, J = 13.67 Hz, H, H−2), 7.56 (s, J = 11.51 Hz, H, H−5), 7.24 (m, 5H, 
H−3c,3d,3e,3f,3g), 5.84 (s, J = 10.18 Hz, 2H, H−3a ), 2.37 (d, J = 0.54 Hz, H, 
H−4` ) ppm. 19F NMR: δ = −56.44 (m, 3F, F−d`), −136.13 (m, 2F, F−c` and F−e`) 
and −143.55 (m, 2F, F−b` and F−f`) ppm. 
 
5.4.8. 1-(2,3,5,6-Tetrafluoropyridyl)-3,4-dimethylimidazolium iodide (33): 
0.193 g of iodomethane in 50 ml of CH2Cl2 was added to (0.196 g) of 1-(2,3,5,6-
tetrafluoropyridyl)-4-methylimidazole (14) and then the mixture has been left for 
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two days at RT. C10H8F4N3I: 373.0914 g.mol
−1
. (51.19 % yield). MS: Calc. 
246.0654. Found. 246.0711 m/z [(M − I)+]. In DMSO (400 MHz), 1H NMR: δ = 
7.95 (m, 1H, H−2), 7.14 (s, J = 18.62 Hz, 1H, H−5), 5.31 (s, J = 6.70 Hz, 3H, 
H−3`) and 2.35 (d, J = 0.49 Hz, 3H, H−4`) ppm, 19F NMR: −86.96 (m, 2F, F−c` 
and F−e`) and −149.26 (m, 2F, F−b` and F−f`) ppm. 
 
5.4.9. 1-(2,3,5,6-Tetrafluoropyridyl)-3-benzyl-4-methylimidazolium bromide 
(34): 
 A solution of 0.775 g of 1-(2,3,5,6-tetrafluoropyridyl)-4-methylimidazole (14) 
and 0.636 g of benzyl bromide in CH2Cl2 was left for two days at RT. 
C16H12F4N3Br: 402.1885 g.mol
−1
. (48.55 % yield). MS: Calc. 322.0967. Found. 
322.0490 m/z [(M − Br)+]. In CDCl3 and DMSO (400 MHz), 
1H NMR: δ = 9.99 
(s, J = 20.06 Hz, 1H, H−2), 8.08 (m, 1H, H−5), 7.45 (m, 5H, H−3c,3d,3e,3f,3g), 
5.68 (s, J = 14.01 Hz, 2H, H−3a) and 3.35 (s, J = 13.39 Hz, 3H, H−4`) ppm. 19F 
NMR: δ = −88.79 (m, 2F, F−c` and F−e`) and −146.87 (m, 2F, F−b` and F−f`) 
ppm. IR (KBr): 3886, 3436, 3121, 3087, 3067, 3024, 2930, 2825, 2775, 2524, 
2396, 2014, 1910, 1839, 1770, 1654, 1625, 1614, 1572, 1498, 1480, 1454, 1442, 
1432, 1420, 1404, 1387, 1368, 1342, 1327, 1263, 1250, 1210, 1199, 1166, 1155, 
1133, 1084, 1036, 1006, 969, 932, 890, 844, 825, 815, 786, 778, 729, 705, 693, 
667, 632, 610, 571, 524, 470 and 460 cm
-1
. Crystallographic data for 34 has been 
shown in table 10. 
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Crystallographic data for 1-(2,3,5,6-tetrafluoropyridyl)-3-benzyl-4-
methylimidazolium bromide. 
_________________________________________________________________ 
 
Formula 
 
C16H12Br2F4N3 
Formula weight 402.20 
Crystal system monoclinic 
Space group P21/c 
a, Å 7.9987(4) 
b, Å 16.4596(9) 
c, Å 12.9003(7) 
Β, o 106.104(2) 
V, Å
3
 1631.75(15) 
Z 4 
Dc (g cm
-3
) 1.637 
Crystal size (mm
3
) 0.25  0.12  0.12 
μ (mm-1) 2.563 
 range (o) 2.06 → 27.99 
Total reflections 21297 
Unique reflections (Rint) 3936(0.0590) 
Observed reflections [I > 2(I)] 2957 
Parameters 217 
Final R indices [I > 2(I)] R1 0.0363, wR2 = 0.0847 
R indices (all data) R1 = 0.0576, wR2 = 0.0918 
Weighting scheme w = 1/[σ2(Fo)
2
 + {0.0403(Fo
2
 + 2Fc
2
)/3}
2
 + 
0.9492(Fo
2
 + 2Fc
2
)/3] 
Max., min. Δρ (eÅ-3) 0.631, -0.593 
Goodness of fit on F
2
 1.029 
__________________________________________________________________ 
Table 10: Estimated standard deviations are given in parentheses. Data were 
collected at 89(2) K with graphite monochromated radiation (λ = 0.71073 Å). 
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5.5. Benzimidazole: 
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Figure 63: The general reaction of polyfluoroarene and benzimidazole derivatives 
(with the labels that have been used to represent the NMR data), (R1= F, CF3, CN, 
CHO), R2= F, CN, R= F, Cl and R
1
= H, CH3. 
 
5.5.1. 1-(2,3,6-Trifluorophathalonitrile)benzimidazole (35): 
 
0.155 g of benzimidazole was dissolved in about 60 ml of THF, and this solution 
was added to 0.198 g of tetrafluorophthalonitrile, then mixture was left for two 
days at room temperature. C15H5F3N4: 298.2265 g.mol
−1
. (165.5 % yield). MS:  
Calc. 299.0545. Found. 299.0401 m/z [(M + H)
+
]. In CDCl3 and DMSO (400 
MHz), 
19F NMR: δ = −109.66 (m, 1F, F−c`), −125.30 (m, 1F, F−b`) and −140.23 
(m, 1F, F−f`) ppm. 1H NMR   spectra show a mixture of the expected product and 
unidentified compounds.      
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5.5.2. 1-(2,3,5,6-Tetrafluorobenzaldehyde)benzimidazole (36): 
 
0.339 g of benzimidazole was dissolved in 70 ml of THF then added to 0.580 g of 
pentafluorobenzaldehyde, and then the solution was left for two days. 
C14H6F4N2O: 294.2078 g.mol
−1
. (50.00 % yield). MS: Calc. 295.0495. Found. 
295.0382 m/z [(M + H)
+
].  In CDCl3 (400 MHz), 
19F NMR: δ = −142.92 (q, J = 
4.55 Hz, J` = 10.80 Hz, 2F, F−c` and F−e`) and −144.28 (q, J = 4.58 Hz, J`= 11.44 
Hz, 2F, F−b` and F−f`) ppm. 1H NMR: δ = 8.23 (s, J = 24.59 Hz, 1H, H−d`), 7.76 
(m, 1H, H−2) and 7.31 (m, 4H, H−5, 6, 7 & 8) ppm. IR (KBr): 3133, 1706, 1651, 
1610, 1521, 1492, 1454, 1405, 1341, 1306, 1266, 1213, 1158, 1131, 1106, 1067, 
1012, 970, 942, 890, 826, 798, 769, 753, 668, 619, 480 and 432 cm
-1
.   
 
5.5.3. 1-(6-Chloro-2,3,5-trifluoropyridyl)benzimidazole (37): 
 
0.172 g of benzimidazole was dissolved in 50 ml of THF then added to 0.295 g of 
3-chloro-2,4,5,6-tetrafluoropyridine, then the solution was left for 48 hrs at room 
temperature. C12H5F3N3CL: 283.6398 g.mol
−1
. (48.45% yield). MS: Calc. 
284.0202. Found. 284.0091 m/z [(M + H)
+
]. CDCl3 and DMSO (400 MHz), 
1
H 
NMR: δ = 8.24 (s, J = 13.00 Hz, 1H, H−2), 7.96 (m, 1H, H−8), 7.46 (m, 2H, H−6 
and H−7) and 7.24 (m, 1H, H−5) ppm. 19F NMR: δ = −69.01 (q, J = 14.83, J` = 
12.62 Hz, 1F, F−c`), −84.17 (q, J = 8.03, J`= 12.59 Hz, 1F, F−e`) and −145.50 (q, 
J = 6.88, J`= 20.58 Hz, 1F, F−b`) ppm. IR (KBr): 3071, 1623, 1609, 1492, 1454, 
1443, 1407, 1350, 1324, 1303, 1282, 1259, 1234, 1180, 1153, 1085, 1071, 1010, 
105 
 
939, 895, 887, 831, 782, 764, 747, 674, 640, 624, 575, 549, 505, 470 and 429 cm
-
1
. 
 
 5.5.4. 1-(2,3,5,6-Tetrafluoropyridyl)benzimidazole (38): 
 
 0.419 g of benzimidazole was dissolved in 50 ml of THF then added to 0.578 g of 
penatfluoropyridine, and then it was left two days at RT. C12H5F4N3: 267.1852 
g.mol
−1
. (75.12% yield). MS: Calc. 268.0498. Found. 268.0520 m/z [(M + H)
+
]. In 
CDCl3 (400 MHz), 
1H NMR: δ = 8.13 (t, J = 1.98 Hz, 1H, H−2), 7.94 (m, 1H, 
H−8), 7.46 (m, 2H, H−6 and H−7), 7.34 (m, 1H, H−5). 19F NMR: δ = −86.16 (m, 
2F, F−c` and F−e`) and −145.80 (m, 2F, F−b` and F−f`) ppm. 
13
C NMR: 144.33 
(dm, J = 247.18 Hz, 3C, C−b, C−f & C-2), 141.34 (m, 1C, C−2), 136.77 (dm, J = 
268.36 Hz, 2C, C−c & C−e), 132.22 (s, J = 15.87 Hz, 1C, C−9), 127.16 (m, 1C, 
C−a), 125.18 (s, J = 21.60 Hz, 1C, C−7), 124.35 (s, J = 21.05 Hz, 1C, C−6), 
121.19 (s, J = 17.27 Hz, 1C, C−8) and 110.4 (t, J = 2.95 Hz, 1C, C−5) ppm. IR 
(KBr): 3074, 1645, 1615, 1532, 1451, 1415, 1337, 1305, 1249, 1194, 1155, 1119, 
1081, 1011, 968, 887, 834, 783, 765, 749, 696, 631, 621, 474 and 430 cm
-1
. 
 
5.5.5. 1-(Heptafluorotolyl)benzimidazole (39): 
 
 0.551 g of octafluorotoluene was added to a dissolved 0.272 g of benzimidazole 
in THF, which then left for two days at RT. C14H5F7N2: 334.1957 g.mol
−1
. 
(84.25% yield). MS: Calc. 335.0419. Found. 335.1400 m/z [(M + H)
+
]. In CDCl3 
and DMSO (400 MHz), 
1H NMR: δ = 7.48 (s, J = 16.47 Hz, 1H, H−2), 7.02 (m, 
106 
 
2H, H−5 & H−8) and 6.62 (m, 2H, H−6 & H−7) ppm. 19F NMR: δ = −51.13 (t, J 
= 21.75 Hz, 3F, F−d`), −134.25 (m, 2F, F−c` & F−e`) and −138.59 (m, 2F, F−b` 
& F−f`) ppm. IR (KBr): 3474, 3114, 3096, 3062, 3038, 3003, 2968, 2945, 2861, 
2796, 2741, 2621, 2541, 1934, 1897, 1862, 1816, 1771, 1737, 1682, 1661, 1620, 
1587, 1530, 1509, 1496, 1478, 1458, 1409, 1364, 1346, 1325, 1301, 1273, 1245, 
1201, 1162, 1135, 1112, 1086, 1003, 996, 958, 933, 914, 898, 887, 847, 810, 795, 
768, 746, 716, ,673, 634, 626, 617, 578, 542, 584 and 419 cm
-1
. 
 
5.5.6. 1-(Heptafluorotolyl)-2-methylbenzimidazole (40): 
 
To a solution of 0.341 g of 2-methylbenzimidazole in THF, 0.587 g of 
octafluorotoluene was added, and left for three days at RT. C15H7F7N2: 348.2225 
g.mol
−1
. (65.66% yield). In CDCl3 and DMSO (400 MHz), MS: Calc. 349.2909. 
Found.349.2909 m/z [(M + H)
+
]. 
1H NMR: δ = 7.43 (m, 2H, H−8 and H−5), 7.11 
(m, 2H, H−6 and H−7) and 2.55 (m, 3H, H−2`) ppm. 19F NMR: δ = −56.07 (t, J = 
21.73 Hz, 3F, F−d`), −138.16 (m, 2F, F−c` and F−e`) and −141.90 (m, 2F, F−b` 
and F−f`) ppm. IR (KBr): 3461, 3179, 3113, 3063, 2997, 2919, 2877, 2849, 2790, 
2724, 2680, 2543, 1921, 1879, 1764, 1624, 1592, 1508, 1488, 1451, 1418, 1387, 
1361, 1318, 1272, 1220, 1197, 1155, 1120, 1069, 1044, 1028, 1004, 924, 896, 
850, 834, 765, 749, 732, 674, 625, 618, 492, 480 and 434 cm
-1
. 
 
 5.5.7. 1-(2,3,5,6-Tetrafluorobenzonitrile)-2-methylbenzimidazole (41): 
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0.322 g of 2-methylbenzimidazole was dissolved in 50ml of THF then added to 
0.475 g of  2,3,4,5,6 pentafluorobenzonitrile and then heated at 60
◦
C for 65:11 h. 
C15H7F4N3: 305.234 g.mol
−1
. (81.53% yield). MS: Calc. 306.0654. Found. 
306.0627 m/z [(M + H)
+
]. In CDCl3 (400 MHz),
 1H NMR: δ = 7.80 (m, 1H, H−8), 
7.38 (m, 2H, H−6,7), 7.04 (m, 1H, H−5) and 3.51 (s, J = 4.91 Hz, 3H, H-2`) ppm. 
19F NMR: δ= −129.48 (m, 2F, F−c` and F−e`) and −140.01 (m, 2F, F−b` and F−f`) 
ppm. IR (KBr): 3436, 2924, 2855, 2248, 1651, 1613, 1504, 1457, 1386, 1324, 
1296, 1269, 1230, 1200, 1163, 1051, 1019, 990, 933, 875, 831, 814, 771, 748, 
678, 656, 544, 499 and 437cm
-1
. 
 
5.5.8. 1-(2,3,5,6-Tetrafluoropyridyl)-2-methylbenzimidazole (42): 
 
0.504 g of 2-methylbenzimidazole was dissolved in 50 ml of THF then added to 
0.598 g of pentafluoropyridine, and the solution was left for 17 days at RT. 
C13H7F4N3: 281.212 g.mol
−1
. (84.85% yield). MS: Calc. 282.0654. Found. 
282.0659 m/z [(M + H)
+
]. In CDCl3 (400 MHz), 
1H NMR: δ = 7.81 (dm, J = 8.03 
Hz, 1H, H−8), 7.35 (m, 2H, H−6 and H−7), 7.04 (dm, J = 7.72 Hz, 1H, H−5), 3.51 
(s, J = 9.54 Hz, 3H, H−2`) ppm. 19F NMR: δ = −129.49 (m, 2F, F−c` and F−e`) 
and (m, 2F, F−b` and F−f`) ppm. 13C NMR: δ = 150.55 (m, 1C, C-2), 144.15 (dm, 
J = 249.96 Hz, 2C, C−b & C−f ), 138.07 (dm, J = 260.54 Hz, 2C, C−c & C−e), 
134.49 (m, 1C, C−9), 127.30 (m,1C, C−a), 124.05 (d, J = 16.07 Hz, 2C, C−6 & 
C−7), 119.95 (s, J = 32.17 Hz, 1C, C−8), 109.48 (s, J = 41.61 Hz, 1C, C−5) and 
13.85 (s, J = 42.45 Hz, 1C, C−2) ppm. IR (KBr): 3401, 1642, 1616, 1516, 1482, 
1454, 1416, 1390, 1368, 1342, 1312, 1283, 1256, 1152, 1136, 1100, 1022, 1013, 
978, 928, 868, 830, 764, 743, 695, 672, 649, 628, 522 and 437 cm
-1
. Elemental 
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analysis, C = Found. 55.55 (Calc. 55.53) %, H = Found. 2.62 (Calc. 2.51) % and 
N = Found. 15.03 (Calc.14.94) %. In 2D NMR, the HSQC spectrum shows that 
H−2` correlates with C−2`, H−5 correlates with C−5, H−6 and H−7 correlates 
with C−6 and C−7, and H−8 correlates with C−8 (Fig. 52, chapter two). In the 
HMBC spectrum shows that H−2` correlates with C−2`and C−2, H−5 correlates 
with C−5, C−4, C−6 and C−7, H−6 and H−7 correlates with C−4, C−5, C−6, C−7, 
C−8 and C−9, H−8 correlates with C−6, C−7, C−8 and C−9 (Fig. 53, chapter 
two). Crystallographic data for 42 has been shown in table 11. 
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Crystallographic data for 1-(2,3,5,6-tetrafluoropyridyl)-2-methylbenzimidazole  
__________________________________________________________________ 
Formula C13H7F4N3 
Formula weight 281.22 
Crystal system orthorhombic 
Space group Pca21 
a, Å 11.0582(4) 
b, Å 7.4614(2) 
c, Å 28.1810(10) 
Β, o ― 
V, Å
3
 2325.20(13) 
Z 8 
Dc (g cm
-3
) 1.607 
Crystal size (mm
3
) 0.38  0.35  0.32 
μ (mm-1) 0.144 
 range (o) 1.45 → 28.01 
Total reflections 15814 
Unique reflections (Rint) 5112(0.0394) 
Observed reflections [I > 2(I)] 4556 
Parameters 361 
Final R indices [I > 2(I)] R1 0.0389, wR2 = 0.1044 
R indices (all data) R1 = 0.0443, wR2 = 0.1086 
Weighting scheme w = 1/[
2
(Fo)
2
 + {0.0592(Fo
2
 + 2Fc
2
)/3}
2
 + 
0.6334(Fo
2
 + 2Fc
2
)/3] 
Max., min. Δρ (eÅ-3) 0.360, -0.425 
Goodness of fit on F
2
 1.040 
__________________________________________________________________ 
Table 11: Estimated standard deviations are given in parentheses. Data were 
collected at 89(2) K with graphite monochromated radiation (λ = 0.71073 Å). 
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5.6. Indazole: 
 
5.6.1. Attempt to synthesize 1-(2,3,5,6-Tetrafluoropyridyl)indazole (43): 
 
 0.378 g of indazole was dissolved in 50 ml of THF then added to 0.535 g of 
pentafluoropyridine, and then the solution was left for a week at RT.  
 
5.7. Benzimidazolium Salt: 
 
5.7.1. 1-(2,3,5,6-Tetrafluoropyridyl)-3-benzyl-benzimidazolium bromide (44): 
 
0.312 g of 1-(2,3,5,6-tetrafluoropyridyl)benzimidazole 38 was dissolved in 50 ml 
of CH2Cl2 with 0.218 g of benzyl bromide, and then the solution was left for two 
days at RT. C19H12F4N3Br: 438.2215 g.mol
−1
. (67.40 % yield). MS: Calc. 
358.0967. Found. 358.0963 m/z [(M − Br)+]. In DMSO (400 MHz), 1H NMR: δ = 
10.46 (s, J = 7.74 Hz, 1H, H−2), 8.60 (m, 4H, H−5,6,7 and 8), 7.34 (m, 5H, 
H−3c,3d,3e,3f,3g) and 5.73 (s, J = 1.97 Hz, 2H, H−3a) ppm. 19F NMR: δ = − 
90.09 (m, 2F, F−c` & F−e`) and −146.68 (m, 2F, F−b` & F−f`) ppm. IR (KBr): 
3639, 3399, 3125, 3058, 3028, 2959, 2926, 1971, 1849, 1805, 1720, 1650, 1622, 
1608, 1590, 1562, 1481, 1458, 1444, 1427, 1407, 1361, 1347, 1325, 1265, 1250, 
1212, 1203, 1192, 1162, 1130, 1084, 1031, 976, 919, 888, 840, 819, 780, 757, 
746, 723, 697, 649, 634, 595, 572, 542, 523, 513, 459 and 421 cm
-1
.  
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Appendix 
 
Figure 64: The 
13
C NMR spectrum of 1-(4-bromo-2,3,5,6-tetrafluorobenzyl)-2-methylimidazole (12). 
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Figure 65: The 
13
C NMR spectrum of 1-(4-iodo-2,3,5,6-tetrafluorobenzyl)-4-methylimidazole (18). 
 
121 
 
 
Figure 66: The 
13
C NMR spectrum of 1-(2,3,5,6-tetrafluoropyridyle)benzimidazole (38). 
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Figure 67: The 
13
C NMR spectrum of 1-(2,3,5,6-tetrafluoropyridyl)-2-methylbenzimidazole (42). 
